[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 291
1. Stojsić J, Milenković B, Radojicić J, Percinkovski M: [Alveolar adenoma -- a rare lung tumour]. Srp Arh Celok Lek; 2007 Jul-Aug;135(7-8):461-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Alveolar adenoma -- a rare lung tumour].
  • INTRODUCTION: Alveolar adenoma belongs to the group of benign epithelial tumours.
  • CONCLUSION: Alveolar adenoma is a rare benign lung tumour, most frequently presented as a solitary pulmonary nodule.
  • After complete surgery, the tumour neither relapses nor malignantly alters.
  • [MeSH-major] Adenoma / diagnosis. Lung Neoplasms / diagnosis. Solitary Pulmonary Nodule / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17929540.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


2. Fatima S, Ahmed Z, Azam M: Benign metastasizing leiomyoma. Indian J Pathol Microbiol; 2010 Oct-Dec;53(4):802-4
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign metastasizing leiomyoma.
  • Benign metastasizing leiomyoma (BML) is a rare condition, affecting predominantly reproductive-age females with uterine leiomyomata and is most often associated with multiple benign-appearing smooth muscle tumors in lungs.
  • Histopathology of one of the pleura-based nodules revealed a neoplasm composed of interlacing fascicles of spindle cells with uniform nuclei.
  • The tumor cells were positive for alpha-smooth muscle actin and negative for CD34 immunohistochemical stain.
  • [MeSH-major] Leiomyoma / diagnosis. Lung Neoplasms / secondary. Pleural Neoplasms / secondary. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Actins / analysis. Adult. Antigens, CD34 / analysis. Female. Histocytochemistry. Humans. Hysterectomy. Immunohistochemistry. Microscopy. Pleural Effusion / diagnosis. Radiography, Thoracic. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21045423.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / ACTA2 protein, human; 0 / Actins; 0 / Antigens, CD34
  •  go-up   go-down


3. Rai SP, Patil AP, Saxena P, Kaur A: Laser resection of endobronchial hamartoma via fiberoptic bronchoscopy. Lung India; 2010 Jul;27(3):170-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endobronchial hamartoma is a rare benign tumor of lung that may present with symptoms of airway obstruction with wheezing, stridor, recurrent pneumonia or atelectasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20931040.001).
  • [ISSN] 0974-598X
  • [Journal-full-title] Lung India : official organ of Indian Chest Society
  • [ISO-abbreviation] Lung India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2946723
  • [Keywords] NOTNLM ; Diode laser / endobronchial hamartoma / fiberoptic bronchoscope / laser resection
  •  go-up   go-down


Advertisement
4. Kourda J, Ismail O, Smati BH, Ayadi A, Kilani T, El Mezni F: Benign myoepithelioma of the lung - a case report and review of the literature. Cases J; 2010;3(1):25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign myoepithelioma of the lung - a case report and review of the literature.
  • INTRODUCTION: Benign myoepithelioma is extremely rare in the lung, to the best of our knowledge; only five cases have been reported in the literature.
  • No mitotic activity or necrosis was seen in the tumor.
  • Immuhistochemically, the tumor cells positive for smooth muscle actin, vimentine, and S100 protein.
  • The diagnosis of benign myoepithelioma of the lung is so confirmed.
  • CONCLUSION: Benign myoepithelioma is a rare pulmonary neoplasm distinct from pleomorphic adenoma, which should be considered in the differential diagnosis of lung nodules.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2005 Nov;237(2):395-400 [16244247.001]
  • [Cites] Rev Pneumol Clin. 2004 Nov;60(5 Pt 1):282-4 [15687912.001]
  • [Cites] Lung Cancer. 1998 Apr;20(1):47-56 [9699187.001]
  • [Cites] Oncology. 1998 Sep-Oct;55(5):431-4 [9732221.001]
  • [Cites] Ultrastruct Pathol. 1995 Sep-Oct;19(5):335-45 [7483010.001]
  • [Cites] Histopathology. 1990 Oct;17(4):311-7 [2175294.001]
  • [Cites] Arch Pathol Lab Med. 1987 Nov;111(11):1082-5 [2821955.001]
  • [Cites] Am J Surg Pathol. 1984 Nov;8(11):803-20 [6209992.001]
  • [Cites] J Histochem Cytochem. 2003 Feb;51(2):133-9 [12533521.001]
  • [Cites] Chest. 2003 Jan;123(1 Suppl):89S-96S [12527568.001]
  • [Cites] Arch Pathol Lab Med. 2001 Nov;125(11):1494-6 [11698012.001]
  • [Cites] Eur J Cardiothorac Surg. 2000 Feb;17(2):187-9 [10731657.001]
  • (PMID = 20180958.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2828429
  •  go-up   go-down


5. Hanley KZ, Facik MS, Bourne PA, Yang Q, Spaulding BO, Bonfiglio TA, Xu H: Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions. Cancer; 2008 Feb 25;114(1):49-56
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
  • Using a mouse monoclonal antibody (L523S) against KOC, KOC expression was investigated in malignant tumors and reactive mesothelial cells in serous effusions.
  • METHODS: Seventy-six cases with paraffin-embedded pleural, pericardial, and peritoneal serous effusion cell blocks including 60 malignant serous effusions (11 malignant pleural mesotheliomas and 49 metastatic carcinomas) and benign pleural effusions (14 cases with reactive mesothelial cells and 2 cases with atypical cells with uncertain significance) were selected for immunohistochemical analysis with L523S, calretinin, and CK5/6.
  • Interestingly, 3 of 16 cases exhibited various degrees of positivity for KOC, 2 of which were diagnosed as lung adenocarcinoma with a recurrence after tumor resection and 1 as malignant pleural mesothelioma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Mesothelioma / diagnosis. Neoplasm Proteins / analysis. Pleural Effusion / diagnosis. Pleural Effusion, Malignant / diagnosis. RNA-Binding Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ascitic Fluid / chemistry. Calbindin 2. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis. Pericardial Effusion / chemistry. S100 Calcium Binding Protein G / analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society
  • (PMID = 18098206.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calb2 protein, mouse; 0 / Calbindin 2; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins; 0 / S100 Calcium Binding Protein G
  •  go-up   go-down


6. Bodner-Adler B, Bartl M, Wagner G: Intravenous leiomyomatosis of the uterus with pulmonary metastases or a case with benign metastasizing leiomyoma? Anticancer Res; 2009 Feb;29(2):495-6
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravenous leiomyomatosis of the uterus with pulmonary metastases or a case with benign metastasizing leiomyoma?
  • BACKGROUND: Intravenous leiomyomatosis (IVL) is defined as an intraluminal growth of benign smooth muscle cells in either venous or lymphatic vessels outside the confines or even in the absence of leiomyomas.
  • Benign metastasizing uterine leiomyoma is defined as a histologically benign uterine smooth muscle tumor that acts in a somewhat malignant fashion and produces benign metastases.
  • Postoperatively, the patient developed a pulmonary embolism and additionally diffuse, multiple nodules of the lungs were detected in the lung scan.
  • An open lung biopsy led to the diagnosis of pulmonary leiomyomatosis.
  • The patient was put on a regimen of gonadotropin-releasing hormone for a total of 6 months and a lung scan after 6 months revealed stable disease.
  • CONCLUSION: Though intravenous leiomyomatosis imitates a malignant neoplasm concerning the pattern of growth and extension, and benign metastasizing leiomyoma produces benign metastases, they must be differentiated histologically from malignant tumors to prevent overtreatment.
  • [MeSH-major] Leiomyoma / pathology. Leiomyomatosis / pathology. Lung Neoplasms / secondary. Uterine Neoplasms / pathology. Vascular Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans


7. Pollefliet C, Peters K, Janssens A, Luijks A, Van Bouwel E, Van Marck E, Germonpre P: Endobronchial lipomas: rare benign lung tumors, two case reports. J Thorac Oncol; 2009 May;4(5):658-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endobronchial lipomas: rare benign lung tumors, two case reports.
  • Endobronchial lipoma is a rare benign lung tumor.
  • We discuss the epidemiology, difficulties in establishing the diagnosis, and the management of this rare condition.
  • [MeSH-major] Bronchial Neoplasms / diagnosis. Lipoma / diagnosis
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19395910.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Kang MW, Han JH, Yu JH, Kim YH, Na MH, Yu JH, Lim SP, Lee Y, Kim JH, Kang DY, Kim JO: Multiple central endobronchial chondroid hamartoma. Ann Thorac Surg; 2007 Feb;83(2):691-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign neoplasm of the lung is rare, and pulmonary hamartoma is the most common form of benign neoplasm of the lung.
  • Reports of multiple endobronchial chondroid hamartomas are rare in the literature, and the awareness of this form of benign disease is important in the differential diagnosis of pulmonary neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17258021.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


9. Ozbudak IH, Dertsiz L, Bassorgun CI, Ozbilim G: Giant cystic chondroid hamartoma of the lung. J Pediatr Surg; 2008 Oct;43(10):1909-11
MedlinePlus Health Information. consumer health - Lung Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cystic chondroid hamartoma of the lung.
  • Pulmonary hamartoma composed of an abnormal mixture of mesenchymal elements is the most common benign neoplasm in the lung.
  • Chest computed tomography revealed a heterogeneous mass filling the middle and the lower lobes of the right lung.
  • We believe this is the first case of 'giant cystic chondroid hamartoma of the lung' described in childhood.
  • We suggest that giant cystic pulmonary hamartoma should be included in the differential diagnosis of large intrathoracic masses in children.
  • [MeSH-major] Cysts / surgery. Hamartoma / surgery. Lung Diseases / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adipose Tissue / pathology. Calcinosis / pathology. Calcinosis / radiography. Calcinosis / surgery. Cartilage / pathology. Child. Diagnosis, Differential. Epithelium / pathology. Humans. Incidental Findings. Lung Neoplasms / diagnosis. Male. Thoracotomy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18926231.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Matsuda E, Okabe K, Kobayashi S, Hirazawa K, Yamamoto H, Tao H, Murakami T, Sugi K: [Pulmonary hamartoma associated with lung cancer]. Kyobu Geka; 2010 Sep;63(10):875-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary hamartoma associated with lung cancer].
  • Pulmonary hamartoma is most common benign tumor of the lung and is not recognised as having a character of malignant transformation.
  • So, longtime radiological observation is not uncommon for patients with diagnosis of pulmonary hamartoma from computed tomography (CT) finding.
  • Although pulmonary hamartoma does not transform to malignancy, high frequency of coexistence hamartoma and lung cancer has been reported.
  • We experienced 14 cases of resected pulmonary hamartoma, and 3 of them had lung cancer, showing that 21.4% of pulmonary hamartoma coexisted with lung cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Hamartoma / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20845697.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Li W, Ni Y, Tu Z, Wu S, Wu Z, Zheng S: Study of telomerase activity in pleural lavage fluid specimens in patients with non-small-cell lung cancer and its clinical significance. Eur J Cardiothorac Surg; 2009 Sep;36(3):460-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of telomerase activity in pleural lavage fluid specimens in patients with non-small-cell lung cancer and its clinical significance.
  • OBJECTIVE: To detect telomerase activity in pleural lavage fluid specimens in patients with non-small-cell lung cancer (NSCLC) and to evaluate its clinical value.
  • METHODS: From July 2005 to May 2007, 167 pleural lavage fluid specimens were obtained from 135 patients with NSCLC and 32 patients with benign lung tumour during operation.
  • Telomerase activity was negative in all 32 patients with benign lung tumour.
  • There was a significant relationship between telomerase activity and pleural extension, T level, N level as well as the clinical TNM (tumour, node, metastasis) stage of lung cancer.
  • CONCLUSION: Telomerase activity is a useful adjunct for cytological method in the diagnosis of pleural micro-metastasis and was related to prognosis in a patient with NSCLC.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / enzymology. Lung Neoplasms / enzymology. Pleural Cavity / enzymology. Pleural Neoplasms / secondary. Telomerase / metabolism
  • [MeSH-minor] Adult. Aged. Clinical Enzyme Tests / methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis. Therapeutic Irrigation

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19502078.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


12. Neuman J, Rosioreanu A, Schuss A, Turi G, Yung E, Trow TK, Williams L, Katz DS: Radiology-pathology conference: sclerosing hemangioma of the lung. Clin Imaging; 2006 Nov-Dec;30(6):409-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiology-pathology conference: sclerosing hemangioma of the lung.
  • Sclerosing hemangioma (SH) is a relatively rare, benign neoplasm of the lung.
  • We report the radiology and pathology of a patient with a SH, with emphasis on the computed tomographic and (18)F-fluorodeoxyglucose positron emission tomography findings, and review the literature on this unusual tumor.
  • [MeSH-major] Fluorodeoxyglucose F18. Lung / radiography. Lung / radionuclide imaging. Positron-Emission Tomography / methods. Pulmonary Sclerosing Hemangioma / diagnosis. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101410.001).
  • [ISSN] 0899-7071
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 18
  •  go-up   go-down


13. Bodtger U, Pedersen JH, Skov BG, Clementsen P: Giant solitary fibrous tumour of the pleura: a rare but usually benign intrathoracic neoplasm. Clin Respir J; 2009 Apr;3(2):109-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant solitary fibrous tumour of the pleura: a rare but usually benign intrathoracic neoplasm.
  • BACKGROUND: Low forced expiratory volume (FEV(1)) and low performance status usually preclude surgical treatment of lung neoplasms.
  • METHODS: A case report of an 83-year-old women with progressing dyspnoea secondary to a huge left-side neoplasm.
  • RESULTS: Work-up reveal an FEV(1) of 0.4 L, and a giant solitary fibrous tumor of the pleura.
  • The tumor was surgically removed in toto without complications: weighting approximately 3 kg, and benign histology.
  • CONCLUSION: Safe and curative surgery is possible in patients with extrapulmonal neoplasm despite poor FEV(1).
  • [MeSH-major] Solitary Fibrous Tumor, Pleural / pathology. Solitary Fibrous Tumor, Pleural / surgery. Thoracic Surgical Procedures / methods
  • [MeSH-minor] Aged, 80 and over. Biopsy, Needle. Dyspnea / diagnosis. Dyspnea / etiology. Female. Follow-Up Studies. Humans. Immunohistochemistry. Postoperative Care / methods. Preoperative Care / methods. Radiography, Thoracic. Severity of Illness Index. Thoracotomy / methods. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20298386.001).
  • [ISSN] 1752-699X
  • [Journal-full-title] The clinical respiratory journal
  • [ISO-abbreviation] Clin Respir J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Hu WD, Liao MY, Chen JK: [Clinical analysis of solitary pulmonary nodule measuring less than 10 mm]. Ai Zheng; 2006 Feb;25(2):217-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Lung cancer is a malignant disease with high incidence and mortality, and its prognosis is to large degree determined by early diagnosis and treatment.
  • X-ray chest film and computed tomography (CT) are important means to discover and diagnose lung cancer.
  • The differences between benign and malignant lesions were compared.
  • Imaging features of SPN of lung cancer were summarized.
  • RESULTS: Of the 102 cases of SPN measuring less than 10 mm, 66 (64.7%) were benign lesions, 25 (24.5%) were primary lung cancer, and 11 (10.8%) were metastatic lung cancer.
  • The benign lesions included inflammatory pseudotumor, benign tumor, lung tuberculosis, and so on.
  • Primary lung cancers, including 6 advanced cases (stage IIA and higher stage), had several radiological features different from benign nodules, such as ill-defined margins, speculation, bronchus or vessel involvement.
  • Also, the enhanced CT value was higher in malignant nodules than in benign nodules except inflammation pseudotumor.
  • The SPNs of metastatic lung cancer had similar radiologic features to those of primary lung cancer.
  • CONCLUSION: SPNs measuring less than 10 mm are mainly composed of benign lung tumor and primary lung cancer.
  • [MeSH-major] Lung Neoplasms. Solitary Pulmonary Nodule
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma / secondary. Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / secondary. Female. Granuloma, Plasma Cell / pathology. Granuloma, Plasma Cell / radiography. Humans. Lung Diseases / pathology. Lung Diseases / radiography. Male. Middle Aged. Retrospective Studies. Smoking. Tomography, X-Ray Computed / methods. Tuberculosis, Pulmonary / pathology. Tuberculosis, Pulmonary / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16480590.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


15. Asioli S, Senetta R, Maldi E, D'Ambrosio E, Satolli MA, Bussolati G, Cassoni P: "Benign" metastatic meningioma: clinico-pathological analysis of one case metastasising to the lung and overview on the concepts of either primitive or metastatic meningiomas of the lung. Virchows Arch; 2007 May;450(5):591-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Benign" metastatic meningioma: clinico-pathological analysis of one case metastasising to the lung and overview on the concepts of either primitive or metastatic meningiomas of the lung.
  • Lung "metastases" of benign meningiomas are rarely described events of biological and clinical interest.
  • We, here, report of a 70-year-old healthy woman found by CT scan to have multiple lesions, the two largest in the right lung on routine examination.
  • The larger lung lesion was a 3-cm node located in the right lung and was removed by wedge resection.
  • The morphological and immunohistochemical features of this lesion, together with the similarity with the original cerebral tumour and its indolent evolution, led to a final diagnosis of "benign" meningioma metastatic to the lung.
  • Lung metastatic meningiomas may be a diagnostic challenge because of their unusual site of presentation and the possible confusion with primitive lung meningiomas or primary mesenchymal lung lesions.
  • They represent a typical example of "benign" tumours that may implant to the lung similar to other tumours, definitely considered benign but reported to rarely present unusual secondary localization.
  • [MeSH-major] Brain Neoplasms / pathology. Lung Neoplasms / secondary. Meningioma / secondary
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Female. Humans. Neoplasm Metastasis / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431673.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


16. Jungraithmayr W, Eggeling S, Ludwig C, Kayser G, Passlick B: Sclerosing hemangioma of the lung: a benign tumour with potential for malignancy? Ann Thorac Cardiovasc Surg; 2006 Oct;12(5):352-4
Genetic Alliance. consumer health - Hemangioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing hemangioma of the lung: a benign tumour with potential for malignancy?
  • Pulmonary sclerosing hemangioma represents a rare neoplasm with variable potential for progression.
  • Intraoperative findings were suggestive of a carcinoid tumour.
  • The tumour was completely removed by lobectomy followed by systematic lymphadenectomy.
  • The histopathological analysis revealed a sclerosing hemangioma, a rare benign neoplasm.
  • Generally, wedge resection is justified in the majority of cases, but in cases of uncertain intraoperative diagnosis, anatomic resection with systematic lymphadenectomy is recommended.
  • [MeSH-major] Pneumonectomy / methods. Pulmonary Sclerosing Hemangioma / diagnosis
  • [MeSH-minor] Adult. Bronchoscopy. Diagnosis, Differential. Female. Humans. Lung Neoplasms / diagnosis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17095978.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Terry NE, Fowler CL: Benign cystic mesothelioma in a child. J Pediatr Surg; 2009 May;44(5):e9-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign cystic mesothelioma in a child.
  • Grossly, it resembled lymphangioma; however, histopathologic diagnosis was benign cystic mesothelioma (BCM), an entity that presents mainly in women of childbearing age.
  • He also underwent resection of a congenital cystic adenomatoid malformation of the right lung.
  • [MeSH-major] Mesothelioma, Cystic / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Ascites / etiology. Cystic Adenomatoid Malformation of Lung, Congenital / complications. Cystic Adenomatoid Malformation of Lung, Congenital / surgery. Diagnosis, Differential. Dyspnea / etiology. Humans. Infant. Lymphangioma / diagnosis. Male. Neoplasm Recurrence, Local / surgery. Pleural Effusion / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433159.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Jin MS, Ha HJ, Baek HJ, Lee JC, Koh JS: Adenomyomatous hamartoma of lung mimicking benign mucinous tumor in fine needle aspiration biopsy: a case report. Acta Cytol; 2008 May-Jun;52(3):357-60
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomyomatous hamartoma of lung mimicking benign mucinous tumor in fine needle aspiration biopsy: a case report.
  • Cytologic features of adenomyomatous hamartoma, a special variant of PH, are not documented in the literature and are confused with epithelial neoplasm in the case of sparse stromal cellularity.
  • Fine needle aspiration biopsy (FNAB) revealed numerous mucinous epithelial cells presenting predominantly in cohesive cellular sheets that suggested benign mucinous epithelial lesion.
  • The patient underwent surgery for the tumor, and it was histologically proven to be an adenomyomatous hamartoma.
  • This case demonstrates the wide spectrum of PH in FNAB and led us to consider PH as a differential diagnosis despite lack of chondromyxoid stromal components.
  • [MeSH-major] Biopsy, Fine-Needle. Hamartoma / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / pathology. Diagnosis, Differential. Humans. Male. Middle Aged. Thoracic Surgery, Video-Assisted. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540306.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Szczepulska-Wójcik E, Langfort R, Roszkowski-Sliz K: [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation]. Pneumonol Alergol Pol; 2007;75(1):57-69
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
  • INTRODUCTION: Histopathological diagnosis of malignant mesothelioma (MM) and differentiating it from tumors infiltrating the pleura is very difficult.
  • Distinguishing benign reactive mesothelial cell proliferation from MM also presents problems.
  • The objective of this study was to evaluate the significance of selected immunohistochemical stains in differentiating MM from non-small cell lung cancers infiltrating the pleura and from benign reactive mesothelial cell proliferation.
  • MATERIAL AND METHODS: The material encompassed 86 cases of MM, 54 cases of NSCLC infiltrating the pleura, and 43 cases of benign reactive mesothelial cell proliferation.
  • Non-small cell lung cancers infiltrating the pleura: Coexpression of cytokeratin and vimentin was found in 17.6% of the cases, positive staining of membranes for EMA, in 13% cases.
  • Benign reactive mesothelial cell proliferation: Protein p53 was present in 9.3% of cases, whereas no positive staining for EMA was found.
  • In the diagnosis of spindle-cell pleural tumors and the fibrous form of MM and benign reactive mesothelial cell proliferation , markers of mesothelial cells are noncontributory.
  • Immunohistochemical staining fails to identify a reactive process, but a diffuse, positive stain for EMA and the presence of protein p53 support the diagnosis of MM.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / analysis. Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / pathology. Mesothelioma / pathology. Neoplasm Proteins / analysis. Neoplasms, Mesothelial / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Aged. Antibodies, Monoclonal / analysis. Diagnosis, Differential. Epithelium / chemistry. Epithelium / pathology. Female. Humans. Hyperplasia / pathology. Immunohistochemistry. Lung / chemistry. Lung / pathology. Male. Middle Aged. Pleura / chemistry. Pleura / pathology. Pleural Effusion / chemistry. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17541913.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


20. Pavlov IuV, Ablitsov IuA, Kharnas SS, Rybin VK, Ablitsov AIu, Pavlov AIu: [Intraoperative ultrasound investigation and laser spectroscopy for diagnosis of cancer in patients with lung tumors]. Khirurgiia (Mosk); 2006;(2):52-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraoperative ultrasound investigation and laser spectroscopy for diagnosis of cancer in patients with lung tumors].
  • Recently intraoperative ultrasonic and laser autofluorescent spectroscopic revision of tumors of the lungs and mediastinal organs is successfully used.
  • Intrasurgical ultrasonic examination of the lungs permits to detect the structure and diffusion of primary lung tumor (invasion of vessels) that influences policy of treatment.
  • Optical spectroscopy permits one to carry out intraoperative rapid diagnosis of benign and malignant lung tumors.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Lung / ultrasonography. Lung Neoplasms / diagnosis. Monitoring, Intraoperative. Pneumonectomy
  • [MeSH-minor] Diagnosis, Differential. Humans. Lasers. Male. Middle Aged. Neoplasm Staging. Spectrometry, Fluorescence / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16715986.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


21. Glaab R, Turina M, Achermann E, Maurer R, Went P, Schöb O: [Alveolar adenoma--a rare pulmonary mass: case report and review of the literature]. Zentralbl Chir; 2009 Sep;134(5):478-80
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Definitive histology following thoracoscopic wedge resection showed the distinctive findings of an alveolar adenoma, a very rare benign tumour of the lung of unknown histogenesis.
  • Its histological features, the benign proliferation of alveolar epithelium and septal mesenchyme, allow for its distinction from other benign lesions of the lung.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma, Bronchogenic / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Hemoptysis / etiology. Humans. Lung / pathology. Male. Middle Aged. Phlebography. Pneumonectomy. Thoracoscopy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Georg Thieme Verlag Stuttgart-New York.
  • (PMID = 19757349.001).
  • [ISSN] 1438-9592
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 5
  •  go-up   go-down


22. de Ruiter GC, Scheithauer BW, Amrami KK, Spinner RJ: Benign metastasizing leiomyomatosis with massive brachial plexus involvement mimicking neurofibromatosis type 1. Clin Neuropathol; 2006 Nov-Dec;25(6):282-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign metastasizing leiomyomatosis with massive brachial plexus involvement mimicking neurofibromatosis type 1.
  • We report the case of a patient who presented with right arm and shoulder pain due to compression of the infraclavicular brachial plexus due to benign metastasizing leiomyomatosis (BML).
  • The diagnosis of BML was not obvious due to its rare nature, the patient's not detailing the specifics of her gynecologic history of having undergone resection of a large uterine leiomyoma and followed by disseminated pelvic leiomyomatous nodules, histologic misinterpretation of an extrauterine lesion of the spine and the brachial plexus as a neurofibroma and the radiologic diagnosis of lung nodules as being "non-specific" in nature.
  • Although a rare condition, BML should be considered in the differential diagnosis of NF and in patients having a history of uterine leiomyoma.
  • [MeSH-major] Brachial Plexus / pathology. Brachial Plexus Neuropathies / etiology. Brachial Plexus Neuropathies / pathology. Leiomyoma / pathology. Neoplasm Metastasis / pathology. Neurofibromatosis 1 / diagnosis. Peripheral Nervous System Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Decompression, Surgical. Diagnosis, Differential. Diagnostic Errors / prevention & control. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Pain / etiology. Pain / pathology. Pain / physiopathology. Spinal Neoplasms / pathology. Spinal Neoplasms / physiopathology. Treatment Outcome


23. Zhang Y, Gomez-Fernandez CR, Jorda M, Ganjei-Azar P: Fine-needle aspiration (FNA) and pleural fluid cytology diagnosis of benign metastasizing pleomorphic adenoma of the parotid gland in the lung: a case report and review of literature. Diagn Cytopathol; 2009 Nov;37(11):828-31
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration (FNA) and pleural fluid cytology diagnosis of benign metastasizing pleomorphic adenoma of the parotid gland in the lung: a case report and review of literature.
  • Lesions that contain abundant benign myoepithelial cells, including pleomorphic adenomas of salivary gland origin, may present a diagnostic challenge in fine-needle aspiration (FNA) specimens.
  • Benign metastasizing pleomorphic adenoma is a rare neoplasm, in which the benign appearing pleomorphic adenoma, without any histological evidence of malignancy, metastasizes to distant sites including lung.
  • In the absence of clinical history of a pre-existing myoepithelial neoplasm, the presence of myoepithelial cells in the lung or any other organs besides salivary glands may create diagnostic difficulty.
  • Here we present the cytologic findings of such a metastatic tumor found in the lung FNA and pleural fluid specimens from a 64-year-old woman, with a history of local recurrent salivary gland pleomorphic adenomas, who presented with multiple bilateral pulmonary nodules and pleural effusion.
  • The diagnosis of benign metastasizing pleomorphic adenoma was made based on clinical information and cytomorphology, and confirmed by immunocytochemistry.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Biopsy, Fine-Needle. Lung Neoplasms / secondary. Parotid Neoplasms / pathology. Pleural Effusion, Malignant / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19582818.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


24. Xu AH, Yin YW, Chen FH: [The value of serum endostatin level in early diagnosis of lung cancer]. Zhonghua Yi Xue Za Zhi; 2006 Jul 18;86(27):1916-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The value of serum endostatin level in early diagnosis of lung cancer].
  • OBJECTIVE: To investigate value of serum endostatin level in early diagnosis of lung cancer.
  • METHODS: ELISA was used to detect the level of serum endostatin at in 40 lung carcinoma patients, 18 males and 4 females, aged 59.50 +/- 14.58.
  • The serum endostatin levels of the lung cancer patients at different clinical stage and of different pathological types were analyzed.
  • Twenty patients with benign lung disease and 20 normal persons were used as controls. RESULTS:.
  • (1) The serum endostatin level of the lung cancer patients was 10.71 +/- 9.99) ng/ml, significantly higher than those of the patients with benign lung diseases and the normal persons (4.79 +/- 1.23 ng/ml and 4.51 +/- 1.14 ng/ml, respectively, both P < 0.01). (2) The serum endostatin level of the lung cancer patients at the stage I and II were 13.63 +/- 13.13 ng/ml and 12.35 +/- 5.79 ng/ml respectively, booth significantly higher than that of the patients at the stage III (6.29 +/- 1.64, P = 0.023 and P = 0.023). (3) There were no significant differences in the serum endostatin level among the lung cancer patients with different pathological types. (4) The serum endostatin level of the lung cancer patients after chemotherapy was 7.83 +/- 1.48 ng/ml, significantly higher than that before the chemotherapy (5.59 +/- 1.74, P = 0.04).
  • CONCLUSION:. (1) Rising in lung cancer at stages I and II, level of serum may probably be used as the a sign in early diagnosis of lung cancer. (2) After chemotherapy the level of endostatin has a trend of rising.
  • [MeSH-major] Endostatins / blood. Lung Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Aged. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Early Diagnosis. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Serologic Tests

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17064531.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Endostatins
  •  go-up   go-down


25. Xu HF, Liu Y, Zhang JH, Zhou RS, Zhou FH, Yuan MH: [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer]. Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb;28(2):108-11
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
  • OBJECTIVE: To study the clinical value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the diagnosis and staging of lung cancer.
  • METHODS: Ninety-four patients with lung nodular changes were examined by CT, 18F-FDG PET and pathology, cytology.
  • Focuses with a SUV > 2.5 were judged as malignant changes, while SUV < or = 2.5 was judged as benign.
  • The sensitivity, specificity, accuracy, positive predictive and negative predictive values of 18F-FDG PET and CT in the diagnosis, and in the evaluation of lymphatic metastasis and remote metastasis of lung lesions were calculated.
  • (1) 58 cases were confirmed to be malignant by surgery or pathological examination, while 36 cases were proved benign by pathology or empirical therapy. (2) The sensitivity, specificity, accuracy, positive and negative predictive values were 69%, 65%, 68%, 82% and 49% respectively for CT; and 91%, 89%, 90%, 93% and 87% respectively for SUV analysis; and 95%, 94%, 95%, 97% and 92% respectively for visual plus SUV methods. (3) Among 34 patients with mediastinal lymph node involvement confirmed by pathology, 18F-FDG PET detected 30 cases, while CT detected only 18 cases (P < 0.01). (4) 18F-FDG PET revealed 19 cases with distant metastases, while CT only discovered 8 cases with distant metastases.
  • CONCLUSION: 18F-FDG PET imaging is of important clinical value in the diagnosis of lung lesions and the staging of malignancy.
  • [MeSH-major] Fluorodeoxyglucose F18. Lung Neoplasms / pathology. Lung Neoplasms / radionuclide imaging. Lymph Nodes / pathology. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Reproducibility of Results. Sensitivity and Specificity. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854393.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


26. Mhawech-Fauceglia P, Saxena R, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, Penetrante R: Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis. J Clin Pathol; 2007 Jun;60(6):709-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis.
  • However, its expression in other tumour types is not fully explored.
  • AIMS AND METHODS: To determine Pax-5 expression in other tumour types, immunohistochemistry was performed on 3758 benign and malignant tumours using multiple tumour microarrays, as well as on whole sections.
  • [MeSH-major] B-Cell-Specific Activator Protein / metabolism. Biomarkers, Tumor / metabolism. Neoplasms / metabolism
  • [MeSH-minor] Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / metabolism. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Diagnosis, Differential. Hodgkin Disease / diagnosis. Hodgkin Disease / metabolism. Humans. Immunoenzyme Techniques. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / metabolism. Neoplasm Proteins / metabolism. Protein Array Analysis / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 2001 Jun;14(6):779-90 [11420047.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):687-92 [15832095.001]
  • [Cites] Trends Genet. 2002 Jan;18(1):41-7 [11750700.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1343-50 [12360049.001]
  • [Cites] Int Urol Nephrol. 2002-2003;34(4):495-501 [14577491.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):994-1000 [14608532.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):122-8 [14745734.001]
  • [Cites] Carcinogenesis. 2004 Oct;25(10):1839-46 [15155532.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):721-7 [15491968.001]
  • [Cites] Mech Dev. 1992 Nov;39(1-2):29-39 [1283313.001]
  • [Cites] Genomics. 1993 Dec;18(3):705-8 [7508415.001]
  • [Cites] C R Acad Sci III. 1995 Jan;318(1):57-66 [7757805.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5709-13 [7777574.001]
  • [Cites] Genes Dev. 1997 Feb 15;11(4):476-91 [9042861.001]
  • [Cites] J Immunol. 1997 Apr 1;158(7):3197-204 [9120274.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 27;94(11):5703-8 [9159136.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Clin Cancer Res. 1995 Feb;1(2):207-14 [9815975.001]
  • [Cites] Gen Physiol Biophys. 1998 Sep;17(3):211-24 [9834843.001]
  • [Cites] BJU Int. 1999 Jun;83(9):1039-44 [10368252.001]
  • [Cites] Nature. 1999 Oct 7;401(6753):556-62 [10524622.001]
  • [Cites] Int J Cancer. 2001 Aug 15;93(4):459-67 [11477548.001]
  • (PMID = 16837628.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / PAX5 protein, human
  • [Other-IDs] NLM/ PMC1955074
  •  go-up   go-down


27. Félix L, Lantuejoul S, Jankowski A, Ferretti G: [Localized pure or mixed ground-glass lung opacities]. J Radiol; 2009 Nov;90(11 Pt 2):1869-92
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Localized pure or mixed ground-glass lung opacities].
  • Localized ground-glass opacities (GGOs) have been recently individualized and account for between 2.9% and 19% of all pulmonary nodules detected in high-risk patients included in CT screening series for lung cancer.
  • These opacities, nodular, lobular or flat, correspond to benign lesions (localised infectious and inflammatory diseases, focal interstitial fibrosis, and atypical alveolar hyperplasia) or malignant lesions (bronchioloalveolar carcinoma, early-stage adenocarcinoma and sometimes metastases).
  • [MeSH-major] Adenocarcinoma / radiography. Adenocarcinoma, Bronchiolo-Alveolar / radiography. Lung Neoplasms / radiography. Radiography, Thoracic / methods. Solitary Pulmonary Nodule / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Algorithms. Biopsy. Clinical Trials as Topic. Diagnosis, Differential. Female. Humans. Hyperplasia. Lung / pathology. Middle Aged. Neoplasm Staging. Prognosis. Pulmonary Alveoli / pathology. Risk Factors. Smoking / adverse effects

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19953078.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 101
  •  go-up   go-down


28. Wang T, Qian X, Wang Z, Wang L, Yu L, Ding Y, Liu B: Detection of cell-free BIRC5 mRNA in effusions and its potential diagnostic value for differentiating malignant and benign effusions. Int J Cancer; 2009 Oct 15;125(8):1921-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of cell-free BIRC5 mRNA in effusions and its potential diagnostic value for differentiating malignant and benign effusions.
  • The detection of circulating nucleic acids has long been explored for the diagnosis of a variety of clinical conditions.
  • Effusions were classified as benign or malignant on the basis of their definitive pathologic or cytologic diagnoses.
  • The expression of cell-free BIRC5 mRNA was statistically significantly higher in the malignant group than in the benign group.
  • BIRC5 mRNA was also significantly different between patients with Stage III and Stage IV non-small cell lung cancers.
  • Determination of BIRC5 and CEA in effusions could enhance diagnostic value in the diagnosis of malignant effusions.
  • [MeSH-major] Ascites / diagnosis. Cell Differentiation. Microtubule-Associated Proteins / genetics. Neoplasms / diagnosis. Pleural Effusion, Malignant / diagnosis. RNA, Messenger / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoembryonic Antigen / genetics. Carcinoembryonic Antigen / metabolism. Female. Humans. Inhibitor of Apoptosis Proteins. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. ROC Curve. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19585499.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Carcinoembryonic Antigen; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / RNA, Messenger
  •  go-up   go-down


29. Mlika M, Ayadi-Kaddour A, Smati B, Ismaïl O, El Mezni F: Benign metastasizing leiomyoma: report of 2 cases and review of the literature. Pathologica; 2009 Feb;101(1):9-11
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign metastasizing leiomyoma: report of 2 cases and review of the literature.
  • Benign metastasizing leiomyoma (BML) is a benign spindle cell lesion affecting women who have undergone hysterectomy for uterine leiomyomas in young adulthood, and subsequently present pulmonary metastases during the peri-menopausal period.
  • BML is a rare benign entity with a debated pathogenesis.
  • [MeSH-major] Leiomyoma / diagnosis. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Uterine Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Hysterectomy. Middle Aged. Neoplasm Metastasis. Perimenopause. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19771765.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 17
  •  go-up   go-down


30. Economidou F, Tzortzaki EG, Schiza S, Antoniou KM, Neofytou E, Zervou M, Lambiri I, Siafakas NM: Microsatellite DNA analysis does not distinguish malignant from benign pleural effusions. Oncol Rep; 2007 Dec;18(6):1507-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microsatellite DNA analysis does not distinguish malignant from benign pleural effusions.
  • Distinguishing malignant from benign pleural effusions using routine cytology is a common diagnostic problem.
  • Twenty-six patients had malignant pleural effusion, including 23 lung cancer and three metastatic non-pulmonary carcinoma.
  • The control group consisted of 22 patients with benign pleural effusions.
  • Only 14 malignancy-associated pleural effusions were cytology-positive for malignant cells (54%), whereas all benign pleural effusions were negative.
  • One out of 22 (4.5%) patients with benign pleural effusion showed LOH in marker D3S134.
  • In conclusion, genetic alterations at the level of microsatellite DNA, were detected only in very few cases of malignant pleural effusions, and in one case of benign pleural effusion.
  • Thus, our data suggest that microsatellite DNA analysis does not facilitate the diagnosis of malignant pleural effusion.
  • [MeSH-major] DNA / genetics. DNA, Neoplasm / genetics. Microsatellite Repeats. Pleural Effusion / physiopathology. Pleural Neoplasms / physiopathology
  • [MeSH-minor] Aged. Aged, 80 and over. Chromosome Mapping. Chromosomes, Human. Female. Genomic Instability. Humans. L-Lactate Dehydrogenase / analysis. Male. Middle Aged. Neoplasm Proteins / analysis. Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17982637.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / Proteins; 9007-49-2 / DNA; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


31. Mao YS, He J, Zheng R, Lin L, Liu L, Cheng Z: [The role of (18)F-FDG DHC SPECT-CT in the diagnosis and staging for lung cancer]. Zhonghua Zhong Liu Za Zhi; 2008 Dec;30(12):933-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of (18)F-FDG DHC SPECT-CT in the diagnosis and staging for lung cancer].
  • OBJECTIVE: To investigate and compare the clinical significance of (18)F-FDG single-photon emission computed tomography and computed tomography (SPECT-CT) in the diagnosis and staging of lung cancer.
  • METHODS: From July 2005 to July 2007, 71 patients with suspected lung cancer received conventional CT and SPECT-CT examination.
  • Fifty-seven of the 71 patients had definite pathological or cytological diagnosis, consisting of 52 malignant lung tumors and 5 benign pulmonary nodules.
  • RESULTS: Taking the pathological diagnosis as gold standard, the sensitivity, specificity and accuracy of diagnosing pulmonary lesions suspected as lung cancer were 84.6% (44/52), 80.0% (4/5), 84.2% (48/57) for conventional CT and 92.3% (48/52), 80.0% (4/5), 91.2% (52/57) for SPECT-CT, respectively.
  • CONCLUSION: SPECT-CT is likely superior to conventional CT in the diagnosing and staging for lung cancer.
  • It can be used as a non-invasive supplementary tool for differential diagnosis between malignant and benign pulmonary lesions and in diagnosis of lymph node > 1 cm in diameter.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Fluorodeoxyglucose F18. Lung Neoplasms / diagnosis. Neoplasm Staging. Tomography, Emission-Computed, Single-Photon / methods
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma / radionuclide imaging. Adult. Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Radiopharmaceuticals. Small Cell Lung Carcinoma / diagnosis. Small Cell Lung Carcinoma / pathology. Small Cell Lung Carcinoma / radiography. Small Cell Lung Carcinoma / radionuclide imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173997.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


32. Wang J, Shi G, Zhang S, Wang Q, Yang X, Li X, Wang H, Zhang H, Song C: [Clinical value of serum TPS, CEA, Pro-GRP and CYFRA21-1 in patients with lung cancer]. Zhongguo Fei Ai Za Zhi; 2010 May;13(5):500-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical value of serum TPS, CEA, Pro-GRP and CYFRA21-1 in patients with lung cancer].
  • BACKGROUND AND OBJECTIVE: Serum tumor markers play important roles in diagnosis, response and prognosis monitoring for lung cancer.
  • The clinical significance of serum level of tissue polypeptide specific antigen (TPS) was investigated in diagnosis, response monitoring and prognosis in patients with lung cancer, compared with carcinoembryonic antigen (CEA), precursor of gastrin-releasing peptide (Pro-GRP) and cytokeratin-19-fragments (CYFRA21-1).
  • METHODS: Blood samples of eighty-two patients with lung cancer before treatment and some after chemotherapy were measured by ELISA for four tumor markers.
  • RESULTS: Compared with lung benign diseases group and health control group, the positive rates and levels of TPS, CEA and Pro-GRP in patients with lung cancer were higher, with statistically significant difference.
  • TPS in extensive-small cell lung cancer was significant higher than that in limited-small cell lung cancer.
  • TPS was an independent prognostic factor of non-small cell lung cancer.
  • CONCLUSION: TPS is valuable to diagnosis, response monitoring for patients with lung cancer, moreover, it maybe a useful factor of prognosis of non-small cell lung cancer.
  • [MeSH-major] Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Keratin-19 / blood. Lung Neoplasms / blood. Peptides / blood. Protein Precursors / blood

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20677649.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / Peptides; 0 / Protein Precursors; 0 / antigen CYFRA21.1; 0 / gastrin-releasing peptide precursor; 0 / tissue polypeptide specific antigen
  •  go-up   go-down


33. Yu ZH, Wang YC, Chen LB, Song Y, Liu C, Xia XY, Lin Q, Ma CY: [Analysis of RASSF1A promoter hypermethylation in serum DNA of non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi; 2008 Apr;30(4):284-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of RASSF1A promoter hypermethylation in serum DNA of non-small cell lung cancer].
  • OBJECTIVE: To detect the hypermethylation status of RASSF1A promoter in serum DNA of non-small cell lung cancer (NSCLC) patient and evaluate its correlation with clinicopathological parameters.
  • METHODS: Serum DNA was extracted from the peripheral blood of 75 NSCLC patients and another 35 patients with benign pulmonary disease and 15 healthy donors.
  • RESULTS: Aberrant methylation of RASSF1A was detected in 23 of 75 (30.7%) cancer patients, but in none of patients with benign pulmonary disease or in healthy donors (P <0.001).
  • CONCLUSION: Hypermethylated RASSF1A promoter is frequently found in the serum DNA of non-small cell lung cancer patient, and RASSF1A may become a promising novel biomarker for diagnosis and prognosis prediction in lung cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / genetics. DNA Methylation. Lung Neoplasms / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Aged. Case-Control Studies. DNA, Neoplasm / blood. DNA, Neoplasm / genetics. Female. Humans. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction / methods. Promoter Regions, Genetic

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18788633.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


34. Quaia E, Tona G, Gelain F, Lubin E, Pizzolato R, Boscolo E, Bussoli L: Integrated fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT compared to standard contrast-enhanced CT for characterization and staging of pulmonary tumors eligible for surgical resection. Acta Radiol; 2008 Nov;49(9):995-1004
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrated fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT compared to standard contrast-enhanced CT for characterization and staging of pulmonary tumors eligible for surgical resection.
  • BACKGROUND: Accurate staging is necessary to determine the appropriate therapy in patients with lung cancer.
  • Few studies have compared integrated fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) and contrast-enhanced CT in the characterization and staging of pulmonary tumors considered eligible for surgical resection.
  • PURPOSE: To compare 18F-FDG PET/CT with standard contrast-enhanced CT for the diagnosis and staging of lung neoplasms eligible for surgical resection.
  • MATERIAL AND METHODS: Seventy-six consecutive patients (56 male, 20 female; mean age+/-SD, 63.4+/-20 years) with 84 pulmonary tumors suspected for malignancy and considered eligible for surgical resection were prospectively enrolled.
  • Seventy-three malignant (65 non-small-cell lung carcinomas, one small-cell lung cancer, two carcinoids, and five metastases) and 11 benign lung tumors (three hamartomas, two sarcoidosis, one amyloidosis, one Wegener granulomatosis, one tuberculosis, and three areas of scarring) were finally diagnosed by histology.
  • Tumor staging was based on the revised American Joint Committee on Cancer.
  • CONCLUSION: In patients with lung neoplasms considered eligible for surgical resection, (18)F-FDG PET/CT versus contrast-enhanced CT revealed higher sensitivity in nodal staging, but lower specificity both in lesion characterization and nodal staging.
  • [MeSH-major] Fluorodeoxyglucose F18. Lung Neoplasms / diagnosis. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Contrast Media. Female. Humans. Image Enhancement. Lung Diseases / diagnosis. Male. Middle Aged. Neoplasm Staging / methods. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18651256.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Contrast Media; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


35. Endo K, Oriuchi N, Higuchi T, Iida Y, Hanaoka H, Miyakubo M, Ishikita T, Koyama K: PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol; 2006 Aug;11(4):286-96

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients.
  • FDG-PET provides information that is not obtainable with other imaging modalities, and is very effective in the diagnosis and management of patients with various types of cancers.
  • PET and/or PET/CT using FDG is clinically useful in the detection of cancer, the differentiation of malignant and benign lesions, the staging of cancer before therapy, and the assessment of cancer therapy, as well as for determining the recurrence after therapy of most cancers, including lung cancer, gastrointestinal cancer, breast cancer, and malignant lymphoma.
  • PET/CT has become the new standard approach to imaging in the diagnosis and management of many cancer patients.
  • [MeSH-major] Fluorodeoxyglucose F18. Neoplasms / diagnosis. Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Tomography, Emission-Computed / methods
  • [MeSH-minor] Breast Neoplasms / diagnosis. Breast Neoplasms / radionuclide imaging. Carcinoma / diagnosis. Carcinoma / radionuclide imaging. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / radionuclide imaging. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / radionuclide imaging. Lymphoma / diagnosis. Lymphoma / radionuclide imaging. Neoplasm Staging / methods. Whole Body Imaging / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16937302.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 51
  •  go-up   go-down


36. Lardinois D, Weder W, Roudas M, von Schulthess GK, Tutic M, Moch H, Stahel RA, Steinert HC: Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer. J Clin Oncol; 2005 Oct 1;23(28):6846-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer.
  • PURPOSE: The aim of this prospective study was to assess the incidence and the nature of solitary extrapulmonary [18F] fluorodeoxyglucose (FDG) accumulations in patients with non-small-cell lung cancer (NSCLC) staged with integrated positron emission tomography and computed tomography (PET/CT) and to evaluate the impact on management.
  • A diagnosis was obtained in 69 of these patients, including 37 (54%) with solitary metastases and 32 (46%) with lesions unrelated to the lung primary.
  • Histopathologic examinations of these 32 lesions revealed a second clinically unsuspected malignancy or a recurrence of a previous diagnosed carcinoma in six patients (19%) and a benign tumor or inflammatory lesion in 26 patients (81%).
  • Benign tumors and inflammatory lesions included eight colon adenomas, four Warthin's tumors, one granuloma of the lower jaw, one adenoma of the thyroid gland, one compensatory muscle activity due to vocal chord palsy, two occurrences of arthritis, three occurrences of reflux esophagitis, two occurrences of pancreatitis, two occurrences of diverticulitis, one hemorrhoidal inflammation, and one rib fracture.
  • CONCLUSION: Solitary extrapulmonary FDG accumulations in patients with newly diagnosed lung cancer should be analyzed critically for correct staging and optimal therapy, given that up to half of the lesions may represent unrelated malignancies or benign disease.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Lung Neoplasms / radionuclide imaging. Neoplasm Metastasis / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Inflammation. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Radiopharmaceuticals. Sensitivity and Specificity. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16192576.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


37. Molina R, Augé JM, Bosch X, Escudero JM, Viñolas N, Marrades R, Ramírez J, Carcereny E, Filella X: Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Tumour Biol; 2009;30(3):121-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology.
  • BACKGROUND: Tumor markers have been extensively studied in lung cancer, reporting some relationship to the histology, but their clinical utility is not clear.
  • METHODS: ProGRP, CEA, SCC, CA 125, CYFRA 21-1 and NSE were studied prospectively in 155 patients with unconfirmed suspicion of lung cancer and in 647 patients with lung cancer: 182 squamous, 205 adenocarcinomas, 19 large-cell lung cancer (LCLC), 175 small-cell lung cancer (SCLC) and 66 unspecific non-small-cell lung cancer (NSCLC).
  • RESULTS: Abnormal tumor marker serum levels were found in less than 5.3% of the patients with benign diseases, excluding CA 125 (21.3%).
  • Tumor markers were related to histological type and tumor extension with significantly higher CEA (p <0.01) and CA 125 (p <0.007) serum levels in adenocarcinomas, SCC (p <0.0001) and CYFRA 21-1 (p <0.008) in squamous tumors and ProGRP (p <0.0001) and NSE (p <0.0001) in SCLC.
  • Tumor markers may be useful in the histological differentiation of NSCLC and SCLC.
  • CONCLUSIONS: Tumor marker determination in patients with suspicious signs of lung cancer suggests, in a few hours, the histological diagnosis in the majority of lung cancer patients.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Squamous Cell / blood. Lung Neoplasms / blood. Peptide Fragments / blood. Small Cell Lung Carcinoma / blood
  • [MeSH-minor] Algorithms. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Staging. Recombinant Proteins / blood. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19506400.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Peptide Fragments; 0 / Recombinant Proteins; 0 / pro-gastrin-releasing peptide (31-98)
  •  go-up   go-down


38. Liu L, Liao GQ, He P, Zhu H, Liu PH, Qu YM, Song XM, Xu QW, Gao Q, Zhang Y, Chen WF, Yin YH: Detection of circulating cancer cells in lung cancer patients with a panel of marker genes. Biochem Biophys Res Commun; 2008 Aug 8;372(4):756-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of circulating cancer cells in lung cancer patients with a panel of marker genes.
  • The current study was undertaken to examine the circulating cancer cells of lung cancer patients using a panel of markers and to evaluate the clinical significance of such tests.
  • Peripheral blood mononuclear cells (PBMCs) from 134 lung cancer patients, 106 benign pulmonary disease, and 80 healthy individuals were isolated and assessed by nested reverse transcription-PCR assay for the expression of three different tumor markers, including tumor specific antigen 9 (TSA-9), Keratin 19 (KRT-19), and Pre-progastrin-releasing peptide (Pre-proGRP).
  • Receiver operating characteristic curve (ROC) analysis showed that the combination of these markers was highly sensitive and specific in differentiating cancer patients from healthy and benign pulmonary disease controls.
  • Of the 134 lung cancer patient blood samples, 84.3% expressed at least one tumor marker.
  • Positivity of more than one marker predicted a poor response to therapy and short survival time in non-small cell lung cancer patients.
  • [MeSH-major] Biomarkers, Tumor / genetics. Lung Neoplasms / diagnosis. Neoplasm Proteins / genetics. Neoplastic Cells, Circulating
  • [MeSH-minor] Humans. Keratin-19 / genetics. Peptides / genetics. Prognosis. Protein Precursors / genetics. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18514066.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / FAM83A protein, human; 0 / Keratin-19; 0 / Neoplasm Proteins; 0 / Peptides; 0 / Protein Precursors; 0 / RNA, Neoplasm; 0 / gastrin-releasing peptide precursor
  •  go-up   go-down


39. Wang F, Wang Z, Yao W, Xie H, Xu J, Tian L: Role of 99mTc-octreotide acetate scintigraphy in suspected lung cancer compared with 18F-FDG dual-head coincidence imaging. J Nucl Med; 2007 Sep;48(9):1442-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of 99mTc-octreotide acetate scintigraphy in suspected lung cancer compared with 18F-FDG dual-head coincidence imaging.
  • The aim of this study was to evaluate the clinical value of tomographic (99m)Tc-octreotide acetate (hereafter, (99m)Tc-octreotide) scintigraphy in the detection of patients with suspected lung cancer in comparison with that of (18)F-FDG dual-head coincidence imaging (DHC).
  • The tumor-to-normal tissue tracer values for both (99m)Tc-octreotide and (18)F-FDG were determined using region of interests and expressed as T/N(r) and T/N(m), respectively.
  • Final diagnosis was confirmed by histopathologic analysis or clinical follow-up.
  • RESULTS: Thirty-one of the 44 patients had lung cancer-6 with small cell lung cancer (SCLC) and 25 with non-small cell lung cancer (NSCLC).
  • Thirteen of the 44 patients had benign lung lesions.
  • In the 31 patients with malignant tumors, all 38 abnormal lymph nodes in 20 patients showed abnormal high focal uptake of (18)F-FDG; only 7 patients with 10 regional lymph adenopathies showed moderate uptake of (99m)Tc-octreotide.
  • Thirteen patients with 39 distant sites of abnormal uptake visualized (imaging stage IV) with (99m)Tc-octreotide included 2 patients with brain metastases, 6 patients with pleural invasion and multiple bone metastasis, 2 patients with contralateral internal lung metastasis and pleural invasion, and 3 patients with only multiple bone metastasis.
  • The final diagnosis was confirmed by histopathology or clinical follow-up.
  • CONCLUSION: The sensitivity of (99m)Tc-octreotide for the detection of lung cancer at the primary lesion was comparable with that of (18)F-FDG coincidence imaging.
  • [MeSH-major] Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Octreotide / analogs & derivatives. Organotechnetium Compounds. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704242.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 99mTc-octreotide; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; RWM8CCW8GP / Octreotide
  •  go-up   go-down


40. Chen F, Li WM, Wang DM, Gao SS, Bao Y, Chen WB, Liu D: [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep;39(5):832-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
  • OBJECTIVE: To investigate the clinical significance of a combination of several serum tumor markers in the diagnosis of lung cancer.
  • METHODS: Serum CEA, CA125, CA199, CYFRA21-1 and NSE were measured with RIA, chromatometrychemoluminescence, ELISA and biochemoluminescence methods respectively in 340 patients with lung cancers at different TNM stages, 120 patients with benign lung diseases, and 45 healthy people.
  • The sensitivities, specificities and accuracies of different combination of those markers for the diagnosis of lung cancers were compared.
  • RESULTS: CYFRA21-1 had the highest sensitivity and accuracy (60.0% and 70.3%) and CA199 had the highest specificity (99.4%) for detecting lung cancers.
  • NSE had the highest sensitivity (76.2%) for detecting small cell lung cancers (SCLC).
  • The combination of several serum tumor markers had higher sensitivities than the single marker for the diagnosis of lung cancers.
  • CONCLUSION: Serum CEA, CA125, CA199, CYFRA21-1 and NSE are helpful markers for the diagnosis of lung cancer.
  • The combination of the markers can improve the sensitivity and accuracy of the diagnosis.
  • [MeSH-major] Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. CA-125 Antigen / blood. Carcinoembryonic Antigen / blood. Keratins / blood. Lung Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Non-Small-Cell Lung / diagnosis. Diagnosis, Differential. Female. Humans. Keratin-19. Male. Middle Aged. Small Cell Lung Carcinoma / blood. Small Cell Lung Carcinoma / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19024326.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / antigen CYFRA21.1; 68238-35-7 / Keratins
  •  go-up   go-down


41. Nishio J, Nabeshima K, Iwasaki H, Naito M: Non-traumatic myositis ossificans mimicking a malignant neoplasm in an 83-year-old woman: a case report. J Med Case Rep; 2010;4:270
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-traumatic myositis ossificans mimicking a malignant neoplasm in an 83-year-old woman: a case report.
  • INTRODUCTION: Myositis ossificans is a benign, self-limiting condition that usually affects young, athletically active men.
  • She had a history of surgery for transverse colon cancer and lung cancer at the ages of 73 and 80, respectively.
  • Clinical and radiological examinations suggested a malignant neoplasm such as metastatic carcinoma or extraskeletal osteosarcoma.
  • A diagnosis of myositis ossificans was made by core needle biopsy.
  • CONCLUSION: Clinicians should consider myositis ossificans as a possible diagnosis for a soft tissue mass in the limb of an older patient, thereby avoiding unnecessarily aggressive therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2008 Jan 1;112(1):193-203 [18040999.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2006 Apr;263(4):331-5 [16133463.001]
  • [Cites] Clin Orthop Relat Res. 1998 Oct;(355):272-81 [9917613.001]
  • [Cites] Clin Radiol. 1995 Oct;50(10):730-1 [7586971.001]
  • [Cites] Clin Radiol. 2002 Dec;57(12):1058-66 [12475528.001]
  • [Cites] Pediatr Pathol. 1992 Mar-Apr;12(2):223-9 [1570239.001]
  • [Cites] Skeletal Radiol. 1992;21(2):87-101 [1566115.001]
  • [Cites] Acta Pathol Jpn. 1985 Sep;35(5):1109-22 [3866484.001]
  • [Cites] Clin Orthop Relat Res. 1993 Nov;(296):213-7 [8222429.001]
  • (PMID = 20704714.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2928249
  •  go-up   go-down


42. Liu J, Zheng S, Yu JK, Zhang JM, Chen Z: Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor. J Zhejiang Univ Sci B; 2005 Jan;6(1):4-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor.
  • To screen and evaluate protein biomarkers for the detection of gliomas (Astrocytoma grade I-IV) from healthy individuals and gliomas from brain benign tumors by using surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) coupled with an artificial neural network (ANN) algorithm.
  • SELDI-TOF-MS protein fingerprinting of serum from 105 brain tumor patients and healthy individuals, included 28 patients with glioma (Astrocytoma I-IV), 37 patients with brain benign tumor, and 40 age-matched healthy individuals.
  • An accuracy of 95.7%, sensitivity of 88.9%, specificity of 100%, positive predictive value of 90% and negative predictive value of 100% were obtained in a blinded test set comparing gliomas patients with healthy individuals; an accuracy of 86.4%, sensitivity of 88.9%, specificity of 84.6%, positive predictive value of 90% and negative predictive value of 85.7% were obtained when patient's gliomas was compared with benign brain tumor.
  • The high sensitivity and specificity achieved by the use of selected biomarkers showed great potential application for the discrimination of gliomas patients from healthy individuals and gliomas from brain benign tumors.
  • [MeSH-major] Astrocytoma / blood. Astrocytoma / diagnosis. Biomarkers, Tumor / blood. Brain Neoplasms / blood. Brain Neoplasms / diagnosis. Diagnosis, Computer-Assisted / methods. Neoplasm Proteins / blood. Peptide Mapping / methods

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Pain. 2003 Apr;102(3):251-6 [12670666.001]
  • [Cites] Curr Med Chem. 2003 May;10(10):831-43 [12678686.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s [12743135.001]
  • [Cites] Lung Cancer. 2003 Jun;40(3):267-79 [12781425.001]
  • [Cites] Curr Pharm Biotechnol. 2004 Feb;5(1):45-67 [14965209.001]
  • [Cites] Curr Opin Biotechnol. 2004 Feb;15(1):24-30 [15102462.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1164-77 [10786889.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Bioinformatics. 2002 Mar;18(3):395-404 [11934738.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1160-9 [12142368.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2541-52 [12171882.001]
  • (PMID = 15593384.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Letter; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC1390751
  •  go-up   go-down


43. GU J, WANG X, ZHAO H, ZHU S, WEN Y, XU H, LI L, CHEN J, ZHOU Q: [Diagnosis value of the detection of CYFRA21-1 in non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi; 2010 Dec;13(12):1118-21
Genetic Alliance. consumer health - Non-small cell lung cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis value of the detection of CYFRA21-1 in non-small cell lung cancer].
  • BACKGROUND AND OBJECTIVE: cytokeratin-19 fragment (CYFRA21-1) is a soluble protein in serum, and may be a useful circulating tumor marker.
  • The aim of this study is to investigate the diagnostic value of the peripheral blood CYFRA21-1 in non-small cell lung cancer (NSCLC).
  • METHODS: the levels of peripheral blood CYFRA21-1 were detected in 107 patients with NSCLC and 51 patients with benign pulmonary diseases by enzyme linked immunosorbent assay, and ROC curve was used to analyse the results.
  • RESULTS: singificant difference of peripheral blood CYFRA21-1 levels was detected between the NSCLC group and benign pulmonary disease group (Chi-Square=47.343, P < 0.001).
  • CONCLUSIONS: as a tumor marker CYFRA21-1 has relative high sensitivity and specificity for the diagnosis of NSCLC.
  • [MeSH-major] Antigens, Neoplasm / blood. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Non-Small-Cell Lung / diagnosis. Keratin-19 / blood

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21159246.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Keratin-19; 0 / antigen CYFRA21.1
  •  go-up   go-down


44. Nadelman CM, Leslie KO, Fishbein MC: "Benign," metastasizing adenomyoepithelioma of the breast: a report of 2 cases. Arch Pathol Lab Med; 2006 Sep;130(9):1349-53
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Benign," metastasizing adenomyoepithelioma of the breast: a report of 2 cases.
  • Adenomyoepitheliomas of the breast are rare tumors composed of a proliferation of 2 cell populations.
  • For the most part, they are considered to be benign, but they locally recur.
  • Those neoplasms that metastasize are deemed to have come from a histologically malignant primary tumor.
  • Herein, we describe 2 cases of metastases of histologically "benign" adenomyoepitheliomas of the breast to the lung.
  • Establishing the diagnosis, determining optimal therapy, and predicting outcome are problematic because of the rarity of this entity.
  • [MeSH-minor] Aged. Female. Humans. Lung Neoplasms / radiography. Middle Aged. Neoplasm Metastasis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16948523.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Antic T, Kapur U, Vigneswaran WT, Oshima K: Inflammatory sarcomatoid carcinoma: a case report and discussion of a malignant tumor with benign appearance. Arch Pathol Lab Med; 2005 Oct;129(10):1334-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory sarcomatoid carcinoma: a case report and discussion of a malignant tumor with benign appearance.
  • Inflammatory sarcomatoid carcinoma is an aggressive tumor with an unusually benign appearance.
  • We report the case of a 65-year-old man with a history of inoperable poorly differentiated carcinoma of the right lung, for which he had received chemoradiotherapy.
  • A new solitary mass was discovered 4 years later in the left lung on surveillance computed tomography.
  • In contrast to sarcomatoid carcinomas, this case highlights the deceptively benign appearance of inflammatory sarcomatoid carcinoma.
  • This leads us to concur with the recommendation to exercise caution when attempting the diagnosis of apparently benign lesions on intraoperative frozen section in patients with high clinical suspicion of malignancy.
  • [MeSH-major] Carcinosarcoma / pathology. Lung Neoplasms / pathology. Plasma Cell Granuloma, Pulmonary / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Bronchiolitis Obliterans / diagnosis. Diagnosis, Differential. Humans. Lymphomatoid Granulomatosis. Male. Neoplasm Invasiveness. Neoplasms, Second Primary. Pneumonia / diagnosis. Sarcoma / diagnosis. Sarcoma / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16196527.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 16
  •  go-up   go-down


46. Wang MZ, Li LY, Zhu ZH, Song ZF: [Application of positron emission tomography in diagnosis and staging for lung cancer]. Zhonghua Jie He He Hu Xi Za Zhi; 2005 Apr;28(4):221-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of positron emission tomography in diagnosis and staging for lung cancer].
  • OBJECTIVE: To determine the usefulness of positron emission tomography with fluoro-2-deoxyglucose (FDG-PET) in lung cancer.
  • METHODS: From September 1999 to April 2003, patients with lung cancer or indeterminate lung lesions on chest CT scan were enrolled, and underwent FDG-PET scanning.
  • RESULTS: Of 104 patients, 64 (60%) had malignancy and 40 (40%) had a benign process.
  • The standard uptake ratio (SUV) in patients with lung cancer was significantly higher than that in patients with benign disease, 4.5 (1.2 - 11.7) and 1.0 (0 - 7.7) respectively.
  • The diagnostic sensitivity, specificity and accuracy of PET imaging for lung cancer were 88%, 85% and 87% respectively, and the diagnostic specificity and accuracy for lung cancer with PET were significant higher than those with CT scan.
  • The specificity and accuracy of lung lesions with a diameter >or= 1.5 cm with SUV method was better than that of lesions with a diameter < 1.5 cm.
  • CONCLUSIONS: PET had advantages in evaluation of lung lesions, and integrated PET and CT were recommended for detecting local lymph node metastasis.
  • [MeSH-major] Lung Neoplasms / pathology. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Aged. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Neoplasm Staging. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854428.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


47. Huang F, Wang XL, Yang L, Yin BX, Geng Y, Li TT: [Clinical value of combined determination of serum and pleural effusion level of CEA,CYFRA21-1, TPS in the diagnosis of lung cancer]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Apr;24(4):370-2
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical value of combined determination of serum and pleural effusion level of CEA,CYFRA21-1, TPS in the diagnosis of lung cancer].
  • AIM: To study the clinical value of combined determination of carcinoembryonic antigen (CEA), cytokeratin-19-fragments (CYFRA21-1) and tissue polypeptide specific antigen (TPS) levels in both serum and pleural effusion in the diagnosis of lung cancer.
  • METHODS: The levels of CEA, CYFRA21-1 and TPS in serum and pleural effusion were measured in 78 patients with lung cancer and 45 patients with benign lung disease by using electrochemiluminescence and ELISA methods respectively.
  • RESULTS: The levels of CEA, CYFRA21-1 and TPS in pleural effusion of patients with lung cancer were much higher than those with benign lung disease (P<0.01).
  • The levels of CEA and TPS in serum of patients with lung cancer were much higher than those with benign lung disease (P<0.05, P<0.01).
  • It was also found that the levels of these tumor markers in pleural effusion were higher and more sensitive than those in sera, especially TPS.
  • TPS showed the highest sensitivity in single tumor marker detection, and TPS+CYFRA21-1+ CEA showed the highest sensitivity and accuracy in combined tumor marker detection for diagnosis of lung cancer in pleural effusion.
  • CONCLUSION: The combined detection of CEA, CYFRA21-1 and TPS in pleural effusion showed higher sensitivity, better accuracy and higher clinical value than those in serum for diagnosis of lung cancer.
  • [MeSH-major] Antigens, Neoplasm / blood. Antigens, Neoplasm / metabolism. Carcinoembryonic Antigen / blood. Carcinoembryonic Antigen / metabolism. Keratin-19 / blood. Keratin-19 / metabolism. Lung Neoplasms / diagnosis. Peptides / blood. Pleural Effusion / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18394347.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / Peptides; 0 / antigen CYFRA21.1; 0 / tissue polypeptide specific antigen
  •  go-up   go-down


48. Edelweiss M, Gupta N, Resetkova E: Preoperative diagnosis of clear cell "sugar" tumor of the lung by computed tomography-guided fine-needle biopsy and core-needle biopsy. Ann Diagn Pathol; 2007 Dec;11(6):421-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative diagnosis of clear cell "sugar" tumor of the lung by computed tomography-guided fine-needle biopsy and core-needle biopsy.
  • Clear cell "sugar" tumor (CCST) of the lung is a very rare benign neoplasm believed to arise from epithelioid cells of perivascular differentiation.
  • This tumor is typically diagnosed by thoracotomy.
  • We here depict an additional case of CCST of the lung that was preoperatively diagnosed by computed tomography-guided transthoracic fine-needle aspiration biopsy and core-needle biopsy.
  • We underscore the importance of cytologic and histologic correlation and the role of ancillary studies in differentiating this lesion from other primary or metastatic clear cell tumors of the lung.
  • [MeSH-major] Lung Neoplasms / pathology. Radiography, Interventional
  • [MeSH-minor] Back Injuries / surgery. Biopsy, Needle. Diagnosis, Differential. Epithelioid Cells / pathology. Humans. Hypertension / complications. Immunohistochemistry. Laminectomy. Male. Middle Aged. Smoking / adverse effects. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18022127.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Khadilkar UN, Kumar S, Prabhu PP, Kamath M: Mucoepidermoid carcinoma of lung: a case report. Indian J Pathol Microbiol; 2007 Jul;50(3):560-2
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of lung: a case report.
  • Mucoepidermoid lung tumours are uncommon neoplasms comprising of 0.2% of all the lung tumours and historically included under the term bronchial adenomas.
  • This is a case report of a bronchial tumour in the hilar region present since 3 years.
  • The neoplasm could be easily classified as a mucoepidermoid tumour of low malignant potential, as it resembled the histologically identical lesion in the main salivary glands.
  • The case is reported for its rarity and for the histological evaluation of the malignant potential in an apparently clinically benign neoplasm.
  • [MeSH-major] Carcinoma, Mucoepidermoid / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Lung / pathology

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883135.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


50. Lee ST, Berlangieri SU, Poon AM, Mitchell P, Pathmaraj K, Tabone K, Byrne AJ, O'Keefe GJ, Knight SR, Clarke CP, Scott AM: Prevalence of occult metastatic disease in patients undergoing 18F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules. Intern Med J; 2007 Nov;37(11):753-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of occult metastatic disease in patients undergoing 18F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules.
  • BACKGROUND: Accurate staging of lung cancer is essential in determining the most appropriate management plan, as detection of occult metastasis can significantly alter management.
  • AIMS: The aims of this study are to determine the prevalence of occult metastasis in patients undergoing 2-(18)F-fluoro-2-deoxy-D-glucose ((18)F-FDG) positron emission tomography (PET) for evaluation of suspected/proven lung carcinoma and correlate pre-PET TNM stage with prevalence of metastasis.
  • Prevalence of occult metastasis was 10/156 (6%) in solitary pulmonary nodules (SPN); 22/319 (7%) and 23/170 (14%) in proven and suspected lung cancer, respectively.
  • Positive predictive value of FDG-PET for metastasis was 8/10 (80%) in solitary pulmonary nodules, 14/20 (70%) and 17/21 (81%) in proven and suspected lung cancer, respectively. (18)F-FDG-avid lesions classified as false positives were patients with cholelithiasis, rib fractures and those with equivocal/negative bone scans or computed tomography on follow up.
  • CONCLUSION: (18)F-FDG PET is predictive for occult metastatic disease in patients with solitary pulmonary nodules and proven or suspected lung cancer and is more likely to be present in all stages, particularly in stage III.
  • PET findings should be actively pursued with correlative investigation to identify benign pathology in patients who remain candidates for curative treatment.
  • [MeSH-major] Lung Neoplasms / epidemiology. Lung Neoplasms / radionuclide imaging. Neoplasm Metastasis / radionuclide imaging. Solitary Pulmonary Nodule / epidemiology. Solitary Pulmonary Nodule / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Predictive Value of Tests. Prevalence. Radiopharmaceuticals. Retrospective Studies

  • Genetic Alliance. consumer health - Pulmonary Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17517082.001).
  • [ISSN] 1445-5994
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


51. Dominkus M, Ruggieri P, Bertoni F, Briccoli A, Picci P, Rocca M, Mercuri M: Histologically verified lung metastases in benign giant cell tumours--14 cases from a single institution. Int Orthop; 2006 Dec;30(6):499-504
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologically verified lung metastases in benign giant cell tumours--14 cases from a single institution.
  • From 1975 to 1997, 649 cases of benign giant cell tumours of the bone were treated at the Istituto Rizzoli.
  • Fourteen patients (2.1%) experienced lung metastases after a mean of 35.2 months.
  • The time interval between the diagnosis and the appearance of the lung metastases ranged from 3 months to 11.9 years.
  • Ten patients showed no evidence of disease, one of these after a second resection of metastases, and four patients presented stable disease with multiple lung metastases.
  • In contrast to previous reports, we could not detect a predominance of the distal radius, but all of the patients had a stage III tumour according to the Enneking criteria of benign lesions.
  • We conclude that even metastatic benign giant cell tumours have an excellent prognosis after adequate resection.
  • [MeSH-major] Bone Neoplasms / pathology. Giant Cell Tumor of Bone / secondary. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Orthop Surg (Hong Kong). 2004 Jun;12(1):55-62 [15237123.001]
  • [Cites] J Bone Joint Surg Am. 1959 Jul;41-A(5):895-904 [13664723.001]
  • [Cites] Ann Thorac Surg. 1973 Nov;16(5):531-5 [4746080.001]
  • [Cites] Cancer. 1980 Oct 1;46(7):1641-9 [7417958.001]
  • [Cites] J Bone Joint Surg Am. 1984 Feb;66(2):269-74 [6693454.001]
  • [Cites] Cancer. 1984 Dec 1;54(11):2564-7 [6498747.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] N Engl J Med. 1988 Feb 25;318(8):517 [3340133.001]
  • [Cites] Clin Orthop Relat Res. 1988 Dec;(237):275-85 [3056645.001]
  • [Cites] J Bone Joint Surg Br. 1989 May;71(3):432-3 [2722935.001]
  • [Cites] AJR Am J Roentgenol. 1992 Feb;158(2):331-4 [1729794.001]
  • [Cites] Clin Orthop Relat Res. 1994 May;(302):219-30 [8168305.001]
  • [Cites] J Bone Joint Surg Am. 1996 Jan;78(1):106-10 [8550667.001]
  • [Cites] J Bone Joint Surg Br. 1998 Jan;80(1):43-7 [9460951.001]
  • [Cites] J Bone Joint Surg Br. 1957 May;39-B(2):346-57 [13438979.001]
  • [Cites] J Bone Joint Surg Am. 1970 Jun;52(4):619-64 [5479455.001]
  • (PMID = 16909252.001).
  • [ISSN] 0341-2695
  • [Journal-full-title] International orthopaedics
  • [ISO-abbreviation] Int Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3172731
  •  go-up   go-down


52. Massion PP, Caprioli RM: Proteomic strategies for the characterization and the early detection of lung cancer. J Thorac Oncol; 2006 Nov;1(9):1027-39
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic strategies for the characterization and the early detection of lung cancer.
  • Biochemical techniques focused on changes in the proteome in benign and malignant conditions have been applied to the study of lung cancer.
  • Although relatively little information is currently available about the human lung proteome, the major goals of the analysis of lung cancer are to better understand tumor biology, to define early detection biomarkers and predictors of tumor behavior, and to identify potential new therapeutic targets.
  • In this review, we summarized the last 10 years of research in this area with emphasis on its application to the early detection of lung cancer.
  • Basic analytical tools, such as two-dimensional gel electrophoresis, mass spectrometry, and protein arrays, are described and placed in the context of lung cancer research.
  • [MeSH-major] Biomarkers, Tumor / blood. Early Diagnosis. Lung Neoplasms / diagnosis. Proteomics / methods
  • [MeSH-minor] Disease Progression. Electrophoresis, Gel, Two-Dimensional. Female. Humans. Male. Mass Spectrometry. Neoplasm Proteins / analysis. Neoplasm Staging. Predictive Value of Tests. Prognosis. Protein Array Analysis. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409991.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA102353
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Number-of-references] 95
  •  go-up   go-down


53. Kushibe K, Kawaguchi T, Nishimoto Y, Takahama M, Tojo T, Taniguchi S: Operative indications for lung cancer with satellite lesions. Asian Cardiovasc Thorac Ann; 2006 Aug;14(4):316-20
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Operative indications for lung cancer with satellite lesions.
  • In deciding the surgical treatment for lung cancer, it is important to differentiate between a small satellite lesion that is probably benign, a pulmonary metastatic lesion, or a double cancer.
  • The operative indications for lung cancer with small satellite lesions detected on preoperative helical computed tomography were retrospectively examined.
  • A definitive diagnosis was made by follow-up computed tomography in 3 of 19 ipsilateral lesions and in 9 of 24 contralateral lesions.
  • The final diagnosis of the satellite lesions was malignant in 13 and benign in 30.
  • Two patients with stage IIb and IIIb disease on clinical staging of the main tumor had pulmonary metastases.
  • Patients with clinical stage I disease had a higher probability that the small lesions were benign or double cancers than those with advanced disease beyond clinical stage I.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Neoplasms, Second Primary / surgery. Solitary Pulmonary Nodule / pathology. Solitary Pulmonary Nodule / surgery
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16868106.001).
  • [ISSN] 1816-5370
  • [Journal-full-title] Asian cardiovascular & thoracic annals
  • [ISO-abbreviation] Asian Cardiovasc Thorac Ann
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


54. Oh SJ, Lee SJ, Lee HY, Paik YH, Lee DK, Lee KS, Chung JB, Yu JS, Yoon DS: [Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas]. Korean J Gastroenterol; 2009 Sep;54(3):162-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas].
  • BACKGROUND/AIMS: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas has a favorable prognosis, but seems to be associated with a high incidence of extrapancreatic tumors.
  • The purpose of this study was to evaluate the incidence and clinicopathological features of extrapancreatic tumors associated with IPMN.
  • These patients were examined for the development of extrapancreatic tumors.
  • RESULTS: Of 37 patients with IPMN, 14 (38%) had 18 extrapancreatic tumors, and 10 (27%) had 13 extrapancreatic malignancies.
  • Five, six, and two extrapancreatic malignancies had been diagnosed before, during, and after the diagnosis of IPMN.
  • Other extrapancreatic tumors included lung cancer (n=2), prostatic cancer (n=1), renal cell carcinoma (n=1), cholangiocellular carcinoma (n=1), urinary bladder cancer (n=1), and gallbladder cancer (n=1), respectively.
  • As benign tumor, there were two gallbladder adenoma, one gastric adenoma, one colonic adenoma and one benign ovarian cystic neoplasm, respectively.
  • CONCLUSIONS: IPMN is associated with high incidence of extrapancreatic tumors, particularly gastric and colorectal neoplasms.
  • Upper gastrointestinal endoscopy and colonoscopy should be done, and systemic surveillance for the possible occurrence of other tumors may allow early detection of extrapancreatic tumor in patients with IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Neoplasms, Multiple Primary / epidemiology. Neoplasms, Second Primary / epidemiology. Pancreatic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Korean J Gastroenterol. 2009 Sep;54(3):196-8 [19844158.001]
  • (PMID = 19844152.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


55. De Wever W, Bruyeer E, Demaerel P, Wilms G, Coolen J, Verschakelen J: Staging of lung cancer. Do we need a diagnostic CT of the brain after an integrated PET/CT for the detection of brain metastases? JBR-BTR; 2010 Mar-Apr;93(2):71-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging of lung cancer. Do we need a diagnostic CT of the brain after an integrated PET/CT for the detection of brain metastases?
  • Brain CT has been recommended in staging of patients with lung cancer because of its usefulness in the detection of metastases.
  • 87 consecutive patients underwent a diagnostic brain CT and a whole-body PET/CT within a period of 3 weeks to stage a known primary tumour.
  • CT examinations were evaluated by two experienced neuroradiologists on the detection of brain lesions (benign and malignant).
  • Considering the clinical diagnosis as standard of reference these figures were for CT1, CT2 and PET/CT respectively 80%, 100%, 100%, 96%, 96% and 66%, 95%, 77%, 93%, 90% and 66%, 97%, 83%, 93%, 91%.
  • [MeSH-major] Brain Neoplasms / radiography. Brain Neoplasms / secondary. Lung Neoplasms / pathology. Lung Neoplasms / radiography. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Brain / radiography. Contrast Media. Female. Humans. Male. Middle Aged. Neoplasm Staging. Observer Variation. Radiographic Image Enhancement / methods. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity. Whole Body Imaging / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20524514.001).
  • [ISSN] 0302-7430
  • [Journal-full-title] JBR-BTR : organe de la Société royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR)
  • [ISO-abbreviation] JBR-BTR
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


56. Kitajima K, Murakami K, Yamasaki E, Domeki Y, Kaji Y, Sugimura K: Performance of FDG-PET/CT for diagnosis of recurrent uterine cervical cancer. Eur Radiol; 2008 Oct;18(10):2040-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Performance of FDG-PET/CT for diagnosis of recurrent uterine cervical cancer.
  • The purpose is to evaluate the accuracy of integrated FDG-PET/CT, compared with PET alone, for diagnosis of suspected recurrence of uterine cervical cancer.
  • A final diagnosis was confirmed by histopathology, radiological imaging, and clinical follow-up for over 1 year.
  • PET/CT resolved the false-positive PET results due to hypermetabolic activity of benign/inflammatory lesions and physiological variants, and was able to detect lung metastasis, local recurrence, peritoneal dissemination, para-aortic lymph node metastasis, and pelvic lymph node metastasis missed by PET alone.
  • [MeSH-major] Fluorodeoxyglucose F18. Image Enhancement / methods. Neoplasm Recurrence, Local / diagnosis. Tomography, X-Ray Computed / methods. Uterine Cervical Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18425518.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


57. Lee JH, Chang JH: Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. Chest; 2005 Oct;128(4):2298-303
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer.
  • STUDY OBJECTIVES: To assess the diagnostic values of carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), and cytokeratin 19 fragments (CYFRA 21-1) as markers of pleurisy in primary lung cancer.
  • PATIENTS: Thirty-four patients with lung cancer and 16 patients with tuberculous pleurisy.
  • MEASUREMENTS AND RESULTS: Levels of CEA, NSE, and CYFRA 21-1 were measured by immunoassay in the serum and pleural fluid of patients with lung cancer and of patients with tuberculous pleurisy.
  • Patients with lung cancer were found to have significantly higher serum and pleural fluid levels of CEA and CYFRA 21-1 than patients with tuberculous pleurisy.
  • Using cutoff values of 5 ng/mL, 20 ng/mL, and 3.3 ng/mL for serum CEA, NSE, and CYFRA 21-1, respectively, the sensitivities and specificities of these tumor markers were as follows for differentiating malignant effusion from benign: CEA, 68% and 93%; NSE, 34% and 93%; and CYFRA 21-1, 45% and 100%.
  • CONCLUSIONS: In the diagnosis of malignant effusion associated with lung cancer, the determinations of CEA and NSE in pleural fluid could enhance diagnostic yield better than those of all three tumor markers.
  • [MeSH-major] Carcinoembryonic Antigen / blood. Keratins / blood. Lung Neoplasms / diagnosis. Phosphopyruvate Hydratase / analysis
  • [MeSH-minor] Antigens, Neoplasm / analysis. Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Case-Control Studies. Humans. Keratin-19. Peptide Fragments / analysis. Pleural Effusion. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236887.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / Peptide Fragments; 0 / antigen CYFRA21.1; 68238-35-7 / Keratins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


58. Roncella S, Ferro P, Franceschini MC, Bacigalupo B, Dessanti P, Sivori M, Carletti AM, Fontana V, Canessa PA, Pistillo MP, Fedeli F: Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin. Diagn Mol Pathol; 2010 Jun;19(2):92-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin.
  • As was reported that human mammaglobin (hMAM) may be expressed in malignant pleural effusions (PEs), we investigated the relevance of hMAM reverse-transcriptase polymerase chain reaction (RT-PCR) for their diagnosis and determination of primary origin.
  • Two hundred and twenty-eight malignant (132 male, 96 female) and 185 benign (132 male, 53 female) PEs were investigated.
  • Statistical analyses evaluated the diagnostic performance parameters in all PEs and in cytologically negative malignant PEs, the association between hMAM and benign or malignant status by the direct index of correlation [diagnostic odds ratio (DOR)], chi test, and P value (P).
  • In addition, the discriminative diagnostic power of hMAM expression, independently in breast cancer, lung cancer (LC), malignant mesothelioma (MM), and other cancers was evaluated.
  • In the entire patient population, hMAM was detected in 45.6% and 5.4% of malignant and benign PEs, respectively, in the male group in 41.7% and 4.5% and in the female group in 51.0% and 7.5% of malignant and benign PEs, respectively.
  • Our results suggest that hMAM RT-PCR may provide information both in the diagnosis of PE and in the search for the primary site of neoplasia, either in male or female patients.
  • [MeSH-major] Breast Neoplasms / complications. Breast Neoplasms / diagnosis. Neoplasm Proteins / genetics. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / etiology. Reverse Transcriptase Polymerase Chain Reaction / methods. Uteroglobin / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Female. Humans. Male. Mammaglobin A. Middle Aged. United States. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20502186.001).
  • [ISSN] 1533-4066
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


59. Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, Takami M, Kodama K: Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients. Interact Cardiovasc Thorac Surg; 2010 Jun;10(6):1009-14
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
  • OBJECTIVES: F18-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT), which allows differentiation between malignant and benign lesions based on difference in tissue glucose metabolism, has become increasingly important in lung cancer diagnosis.
  • This study examined the clinical value of FDG-PET/CT in a large number of patients with non-small cell lung cancer (NSCLC) after potentially curative surgery.
  • All the 241 patients had undergone potentially curative surgery for NSCLC >6 months before FDG-PET/CT and their pathologic stages were stage I and II according to the tumor-node-metastasis (TNM) classification.
  • A final diagnosis of recurrence was confirmed by histologic or cytologic examination of the disease or by clinical and radiologic follow-up image analysis.
  • Details of false results and incidental detection of diseases other than recurrent lung cancer by FDG-PET/CT was also analyzed.
  • Malignancies other than recurrence were detected in nine of all 241 patients (4%) including five second primary lung cancers.
  • FDG-PET/CT is useful not only for diagnosis of recurrence but also for detection of other diseases.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Pneumonectomy. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. False Negative Reactions. False Positive Reactions. Female. Humans. Incidental Findings. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20197344.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


60. Zhao X, Wang M: [The role of TBNA in diagnosis and treatment of lung diseases]. Zhongguo Fei Ai Za Zhi; 2010 May;13(5):396-400
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of TBNA in diagnosis and treatment of lung diseases].
  • In the last 30 years, clinical application oftransbronchial needle aspiration (TBNA) has proved its efficiency, accuracy, safety and cost-effectiveness, particularly in diagnosing and staging lung cancer as well as in diagnosing benign diseases.
  • In the future, EUBS-TBNA may have applications in both benign and malignant lung diseases as a routine examination.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Bronchi / pathology. Lung Neoplasms / diagnosis
  • [MeSH-minor] Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20677630.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 31
  •  go-up   go-down


61. Goto T, Maeshima A, Oyamada Y, Kato R: Definitive diagnosis of multiple myeloma from rib specimens resected at thoracotomy in a patient with lung cancer. Interact Cardiovasc Thorac Surg; 2010 Jun;10(6):1051-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Definitive diagnosis of multiple myeloma from rib specimens resected at thoracotomy in a patient with lung cancer.
  • Chest X-ray showed a mass shadow in the right upper lung field.
  • Serum immunoelectrophoresis detected IgG-lambda monoclonal protein; therefore, we suspected the coexistence of multiple myeloma, amyloidosis, benign macroglobulinemia, or benign monoclonal gammopathy.
  • The postoperative pathological diagnosis was SCC of the lung (p-T2N0M0, stage IB).
  • Herein, we report a patient with lung cancer in whom multiple myeloma was definitively diagnosed from rib specimens resected at thoracotomy.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Multiple Myeloma / diagnosis. Neoplasms, Multiple Primary. Ribs / pathology. Thoracotomy
  • [MeSH-minor] Biomarkers, Tumor / analysis. Humans. Immunohistochemistry. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed


62. Li CF, Wang JW, Huang WW, Hou CC, Chou SC, Eng HL, Lin CN, Yu SC, Huang HY: Malignant diffuse-type tenosynovial giant cell tumors: a series of 7 cases comparing with 24 benign lesions with review of the literature. Am J Surg Pathol; 2008 Apr;32(4):587-99

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant diffuse-type tenosynovial giant cell tumors: a series of 7 cases comparing with 24 benign lesions with review of the literature.
  • BACKGROUND: Malignant diffuse-type tenosynovial giant cell tumor (D-TSGCT), an unusual sarcoma with concurrent or previous benign D-TSGCTs, poses challenges to diagnosis and prognostication.
  • Twenty-four benign D-TSGCTs were also statically compared to analyze the diagnostic values of various variables.
  • These tumors were 5 to 17 cm (mean, 9.4) and located within or near the large joints of extremities.
  • Histologically, areas of benign D-TSGCTs blended abruptly or gradually with frank sarcomas composed of pleomorphic, spindle, or enlarged oval cells, forming malignant fibrous histiocytomalike (n = 4), fibrosarcomatous (n = 1), myxosarcomatous (n = 1), or giant cell tumorlike (n = 1) patterns.
  • One patient experienced recurrences twice, and another 3 developed metastases to the lymph nodes (n = 2), lung (n = 1), or vertebrae (n = 1), with 1 dying from disseminated diseases.
  • An older age (P = 0.003), a larger size (P = 0.036), tumor necrosis (P < 0.001), atypical mitoses (P < 0.001), and Ki-67 overexpression (P < 0.001) appeared preferentially in malignant lesions, but these parameters had overlap between few benign and malignant tumors.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Giant Cell Tumors / pathology. Neoplasms, Second Primary / pathology. Sarcoma, Synovial / pathology
  • [MeSH-minor] Aged. Anaplasia. Data Interpretation, Statistical. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Middle Aged. Mitosis. Necrosis. Neoplasm Metastasis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301053.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  • [Number-of-references] 22
  •  go-up   go-down


63. Ioncica AM, Malos A, Crisan E, Popescu C, Saftoiu A, Ciurea T: State-of-the art endoscopic imaging in lung cancer: should specialties collide or concur? J Gastrointestin Liver Dis; 2010 Mar;19(1):93-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] State-of-the art endoscopic imaging in lung cancer: should specialties collide or concur?
  • Endoscopic ultrasound has been recently established as a routine diagnostic and staging procedure in lung cancer patients, mainly because of the possibility of tissue sampling.
  • Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) permits the assessment of the tumors in the anterior mediastinum.
  • Based on previously published literature, it is obvious that this minimally invasive procedure now offers the possibility of tissue diagnosis in mediastinal masses including primary tumours or secondary lesions from both benign and malignant diseases.
  • [MeSH-major] Biopsy, Fine-Needle. Bronchoscopy. Echocardiography, Transesophageal. Endosonography. Lung Neoplasms / diagnosis. Ultrasonography, Interventional
  • [MeSH-minor] Diagnosis, Differential. Humans. Neoplasm Staging. Predictive Value of Tests

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20361084.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  •  go-up   go-down


64. Santini M, Fiorello A, Mansi L, Rambaldi PF, Vicidomini G, Busiello L, Messina G, Nargi P: The role of technetium-99m hexakis-2-methoxyisobutyl isonitrile in the detection of neoplastic lung lesions. Eur J Cardiothorac Surg; 2009 Feb;35(2):325-31
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of technetium-99m hexakis-2-methoxyisobutyl isonitrile in the detection of neoplastic lung lesions.
  • OBJECTIVE: Our goal was to determine the role of technetium-99m hexakis-2-methoxyisobutyl isonitrile ((99m)Tc-MIBI) in the detection of neoplastic lung lesions.
  • MATERIALS AND METHODS: We prospectively studied 79 consecutive patients with indeterminate lung lesion between January 2006 and September 2007.
  • In addition, semiquantitative analysis was made by calculating tumor/contralateral normal lung ratio (T/N).
  • Finally, the scintigraphic findings were correlated to the histopathological diagnosis obtained by invasive procedure or confirmation of instrumental exams.
  • RESULTS: Sixty patients had a malignant lesion: 44 squamous cell carcinoma, 7 adenocarcinomas, 4 large cell carcinoma, 1 small cell lung cancer, and 4 metastases.
  • Nineteen patients had a benign disease.
  • The mean size+/-standard deviation of benign nodules was 3.3+/-1.71 cm (range 2-6 cm). (99m)Tc-MIBI SPECT delineated focal lesions with an increase in tracer accumulation in 55/60 malignant lesions; in 5/60 malignant lesions was negative.
  • In patients with neoplastic lesion, the mean T/N ratio value+/-standard deviation was 1.72+/-0.35 whereas in patients with benign lesions was 1.14+/-0.25.
  • CONCLUSION: Our experiences seem to confirm that (99m)Tc-MIBI SPECT is a reliable diagnostic tool in the finding of lung cancer particularly cases in which radiological evaluation is indeterminate.
  • [MeSH-major] Lung Neoplasms / radionuclide imaging. Radiopharmaceuticals. Technetium Tc 99m Sestamibi
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Epidemiologic Methods. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Tomography, Emission-Computed, Single-Photon / methods. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18996706.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


65. Suga Y, Miyajima K, Oikawa T, Maeda J, Usuda J, Kajiwara N, Ohira T, Uchida O, Tsuboi M, Hirano T, Kato H, Ikeda N: Quantitative p16 and ESR1 methylation in the peripheral blood of patients with non-small cell lung cancer. Oncol Rep; 2008 Nov;20(5):1137-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative p16 and ESR1 methylation in the peripheral blood of patients with non-small cell lung cancer.
  • Inactivation of the p16 and ESR1 tumor suppressor genes by promoter lesion methylation has been reported in many tumor types, including lung cancer.
  • We examined the blood of 95 non-small cell lung cancer patients (66 cases of adenocarcinoma, 23 of squamous cell carcinoma and 6 of large cell carcinoma) and 30 controls consisting of normal subjects and benign disease patients to determine the methylation ratios of p16 and ESR1 using real-time PCR.
  • For both genes, there was a statistically significant difference in the methylation ratio between non-small cell lung cancer patients and controls (p16; p<0.01, ESR1; p<0.001).
  • Evaluation of p16 and ESR1 promoter methylation in blood using real-time PCR appears to be very useful for lung cancer diagnosis and there is some possibility that these methylated genes might come to represent useful biomarkers for the early detection of lung cancer.
  • Our study results also suggested that comparative evaluation of the methylation ratio before and after surgery might be a powerful tool to predict the prognosis of lung cancer patients.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / blood. DNA Methylation. Estrogen Receptor alpha / genetics. Genes, p16. Lung Neoplasms / blood
  • [MeSH-minor] Age Factors. Aged. Carcinoembryonic Antigen / blood. DNA, Neoplasm / blood. DNA, Neoplasm / genetics. Female. Hematologic Tests / methods. Humans. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Smoking / adverse effects

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949413.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / DNA, Neoplasm; 0 / Estrogen Receptor alpha; 0 / estrogen receptor alpha, human
  •  go-up   go-down


66. Hofman MS, Smeeton NC, Rankin SC, Nunan T, O'Doherty MJ: Observer variation in FDG PET-CT for staging of non-small-cell lung carcinoma. Eur J Nucl Med Mol Imaging; 2009 Feb;36(2):194-9
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Observer variation in FDG PET-CT for staging of non-small-cell lung carcinoma.
  • The aim of this study was to evaluate agreement amongst experienced readers in staging non-small-cell lung cancer (NSCLC) with PET-CT.
  • Individual mediastinal lymph node stations were assessed as benign/inflammatory, equivocal or malignant, and AJCC N and M stage were also assigned.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / pathology. Fluorodeoxyglucose F18. Neoplasm Staging / methods. Positron-Emission Tomography / statistics & numerical data. Tomography, X-Ray Computed / statistics & numerical data
  • [MeSH-minor] Humans. Neoplasm Metastasis. Observer Variation. Referral and Consultation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18828012.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


67. Lu G, Wang Z, Zhu H, Chang L, Chen Y, Wu J, Zhao Y: The advantage of PET and CT integration in examination of lung tumors. Int J Biomed Imaging; 2007;2007:17131

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The advantage of PET and CT integration in examination of lung tumors.
  • PURPOSE: To evaluate the diagnosis value of integrated positron emission tomography and computed tomography (PET/CT) with lung masses, this study emphasized the correlation between tumor size and maximum standardized uptake value (SUVmax) in selected regions of interest (ROI) of lung masses.
  • RESULTS: Among the 85 patients with lung masses, 59 patients presented with pulmonary malignant neoplasm and 26 patients with benign lesions.
  • The size of pulmonary malignant neoplasm in the 59 patients was apparently correlated with the ROI's SUVmax (r=0.617, P<.001).
  • However, the size of pulmonary benign mass in the 26 patients was not correlated with the SUVmax.
  • CONCLUSION: PET/CT is of greater value in characterization of lung masses than PET and CT performed separately.
  • The examination of lung tumor can be further specified by the correlation between the size of pulmonary malignant neoplasm and the ROI's SUVmax.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2002 Jul;43(7):871-5 [12097455.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Dec;29(12):1639-47 [12458399.001]
  • [Cites] Chest. 1997 Aug;112(2):416-22 [9266877.001]
  • [Cites] JAMA. 2001 Feb 21;285(7):914-24 [11180735.001]
  • [Cites] Radiographics. 2000 Jan-Feb;20(1):59-66 [10682771.001]
  • [Cites] AJR Am J Roentgenol. 2002 May;178(5):1053-7 [11959700.001]
  • [Cites] Nucl Med Commun. 2003 Nov;24(11):1129-37 [14569166.001]
  • [Cites] Lung Cancer. 2004 Jul;45(1):19-27 [15196730.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6A):4153-7 [11911310.001]
  • [Cites] Radiology. 2006 Apr;239(1):34-49 [16567482.001]
  • [Cites] Ann Thorac Surg. 2005 Mar;79(3):984-8; discussion 989 [15734419.001]
  • [Cites] Chest. 2003 Sep;124(3):893-901 [12970014.001]
  • (PMID = 18274652.001).
  • [ISSN] 1687-4188
  • [Journal-full-title] International journal of biomedical imaging
  • [ISO-abbreviation] Int J Biomed Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2233876
  •  go-up   go-down


68. Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T: Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol; 2008 Nov;3(11):1317-24
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
  • INTRODUCTION AND METHODS: We investigated the diagnostic and prognostic value of soluble mesothelin-related proteins (SMRP) in sera from patients with newly diagnosed malignant pleural mesothelioma (MPM) (n = 100), MPM patients at tumor relapse (n = 29), primary lung cancer (n = 139), and benign asbestosis (n = 75) using Mesomark--enzyme-linked immunosorbent assay kit (Fujirebio Diagnostics, Malvern, PA).
  • RESULTS: SMRP concentrations were significantly higher in MPM compared with benign asbestosis (p < 0.001) or lung cancer (p < 0.001).
  • CONCLUSION: In conclusion, SMRP add limited information to the diagnosis of MPM.
  • [MeSH-major] Asbestosis / diagnosis. Biomarkers, Tumor / blood. Lung Neoplasms / diagnosis. Membrane Glycoproteins / blood. Mesothelioma / diagnosis. Pleural Effusion, Malignant / diagnosis
  • [MeSH-minor] Antigens, Neoplasm / blood. Female. GPI-Linked Proteins. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Asbestosis.
  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18978568.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


69. Koh MS, Tee A, Wong P, Antippa P, Irving LB: Advances in lung cancer diagnosis and staging: endobronchial ultrasound. Intern Med J; 2008 Feb;38(2):85-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in lung cancer diagnosis and staging: endobronchial ultrasound.
  • BACKGROUND: Endobronchial ultrasound (EBUS) is an accurate and relatively less invasive procedure for the diagnosis of lung lesions and mediastinal lymph node staging for lung cancer.
  • METHODS: Consecutive patients who underwent EBUS-transbronchial lung biopsy (EBUS-TBLB) for biopsy of peripheral pulmonary lesions or for transbronchial needle aspiration (TBNA) of mediastinal lymph node enlargement were included in this audit.
  • The average size of the lung lesions biopsied was 3.5 cm and 62% were located in the upper lobes.
  • Malignancy was diagnosed in 14 cases and a benign aetiology in four.
  • Malignancy was diagnosed in 10 cases on TBNA and 4 cases had benign pathology.
  • CONCLUSION: EBUS is safe and an effective method for both, diagnosis of peripheral pulmonary lesions and staging for lung cancer.
  • [MeSH-major] Bronchi / pathology. Endosonography. Lung Neoplasms / pathology. Lung Neoplasms / ultrasonography. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Female. Humans. Male. Middle Aged. Neoplasm Staging. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Intern Med J. 2008 Feb;38(2):75-6 [18290825.001]
  • (PMID = 17916175.001).
  • [ISSN] 1445-5994
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


70. Keylock JB, Galvin JR, Franks TJ: Sclerosing hemangioma of the lung. Arch Pathol Lab Med; 2009 May;133(5):820-5
Genetic Alliance. consumer health - Hemangioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing hemangioma of the lung.
  • We present a brief review of sclerosing hemangioma, an uncommon but histologically distinctive neoplasm of the lung.
  • Sclerosing hemangiomas typically present as asymptomatic, peripheral, solitary, well-circumscribed lesions in women with a mean age at diagnosis in the fifth decade.
  • Sclerosing hemangioma of the lung is generally considered to be a benign lesion, and surgical excision is curative without the need for additional treatment.
  • [MeSH-major] Lung / pathology. Pulmonary Sclerosing Hemangioma / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Carcinoma / diagnosis. Carcinoma / secondary. Diagnosis, Differential. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Male. Prognosis. Radiography, Thoracic. Respiratory Mucosa / metabolism. Respiratory Mucosa / pathology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415961.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 29
  •  go-up   go-down


71. Zissimopoulos A, Stellos K, Matthaios D, Petrakis G, Parmenopoulou V, Babatsikou F, Matthaiou E, Theodosiadou E, Hountis P, Koutis C: Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy. J BUON; 2009 Jul-Sep;14(3):463-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
  • PURPOSE: In this study we evaluated the clinical usefulness of serum pro-I collagen peptide (PICP) and I collagen telopeptide (ICTP) as indicators of early bone metastases in patients with breast (BC), lung (LC), urinary bladder (UBC) and prostate cancer (PC).
  • ICTP and CA 15-3 were the most reliable markers for early diagnosis of bone metastases in BC.
  • Furthermore, PICP and PSA levels were significantly higher in patients with PC and bone metastases in comparison to patients with benign prostate hyperplasia (BPH) (p <0.0001) or in patients with PC without bone metastases (p <0.0005 for PICP and p <0.0001 for PSA).
  • CONCLUSION: ICTP and CA 15-3 are the most reliable markers for early diagnosis of bone metastases in BC patients.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Collagen Type I / metabolism
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / pathology. Carcinoembryonic Antigen / metabolism. Female. Humans. Immunoradiometric Assay. Lung Neoplasms / pathology. Male. Middle Aged. Mucin-1 / metabolism. Neoplasm Metastasis. Prostate-Specific Antigen / metabolism. Prostatic Neoplasms / pathology. Sensitivity and Specificity. Tomography, Emission-Computed. Urinary Bladder Neoplasms / pathology


72. Cetani F, Ambrogini E, Viacava P, Pardi E, Fanelli G, Naccarato AG, Borsari S, Lemmi M, Berti P, Miccoli P, Pinchera A, Marcocci C: Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol; 2007 May;156(5):547-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?
  • The aim of our study was to extend parafibromin studies in a series of benign and malignant parathyroid tumors and cross-validate the results of immunohistochemistry with those of HRPT2 analysis.
  • DESIGN AND PATIENTS: We performed parafibromin and cyclin D1 immunostaining and HRPT2 gene analysis using loss of heterozygosity studies and sequencing analysis in parathyroid specimens from 11 patients with carcinoma (eleven primary tumors, one skin, and four lung metastases), 22 with sporadic adenomas, and 4 with atypical adenomas.
  • In clinical practice, these tests could be particularly useful in the subset of parathyroid tumors with equivocal histological examination.

  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17468190.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDC73 protein, human; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Proteins; 136601-57-5 / Cyclin D1
  •  go-up   go-down


73. Ung YC, Maziak DE, Vanderveen JA, Smith CA, Gulenchyn K, Lacchetti C, Evans WK, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care: 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. J Natl Cancer Inst; 2007 Dec 5;99(23):1753-67
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review.
  • Lung cancer is the leading cause of cancer-related death in industrialized countries.
  • The overall mortality rate for lung cancer is high, and early diagnosis provides the best chance for survival.
  • Diagnostic tests guide lung cancer management decisions, and clinicians increasingly use diagnostic imaging in an effort to improve the management of patients with lung cancer.
  • This systematic review, an expansion of a health technology assessment conducted in 2001 by the Institute for Clinical and Evaluative Sciences, evaluates the accuracy and utility of 18fluorodeoxyglucose positron emission tomography (PET) in the diagnosis and staging of lung cancer.
  • PET appears to have high sensitivity and reasonable specificity for differentiating benign from malignant lesions as small as 1 cm.
  • PET appears superior to computed tomography imaging for mediastinal staging in non-small cell lung cancer (NSCLC).
  • PET has not been studied as extensively in patients with small-cell lung cancer, but the available data show that it has good accuracy in staging extensive- versus limited-stage disease.
  • Although the current evidence is conflicting, PET may improve results of early-stage lung cancer by identifying patients who have evidence of metastatic disease that is beyond the scope of surgical resection and that is not evident by standard preoperative staging procedures.
  • Further trials are necessary to establish the clinical utility of PET as part of the standard preoperative assessment of early-stage lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Carcinoma, Non-Small-Cell Lung / secondary. Fluorodeoxyglucose F18. Lung Neoplasms / pathology. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Diagnosis, Differential. Humans. Lymphatic Metastasis. Mediastinal Neoplasms / radionuclide imaging. Mediastinal Neoplasms / secondary. Neoplasm Staging. Radiopharmaceuticals. Sensitivity and Specificity. Solitary Pulmonary Nodule / pathology. Solitary Pulmonary Nodule / radionuclide imaging. Technology Assessment, Biomedical

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2007 Dec 5;99(23):1741-3 [18042929.001]
  • (PMID = 18042932.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 101
  •  go-up   go-down


74. Paci M, Cavazza A, Annessi V, Ricchetti T, Rapicetta C, Sgarbi G: Cystic fibrohistiocytic tumor of the lung presenting as a solitary lesion. Rare Tumors; 2010;2(1):e14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic fibrohistiocytic tumor of the lung presenting as a solitary lesion.
  • Cystic fibrohistiocytic tumor of the lung is a rare neoplasm.
  • In many cases it represents a metastasis from a benign or low-grade fibrohistiocytic tumor of the skin, but occasionally it may be primary.
  • Microscopy of the apical segmentectomy showed a cystic fibrohistiocytic tumor, whereas the nodule of the lower lobe was an intraparenchymal lymph node.
  • The patient is alive with no tumor recurrence.
  • The differential diagnosis includes Langerhans cell histiocytosis, lymphangioleiomyomatosis, pleuropulmonary blastoma, and metastatic endometrial stromal sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139943.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994490
  • [Keywords] NOTNLM ; cystic fibrohistiocytic tumor / lung neoplasms / mesenchymal cystic hamartoma / mesenchymal tumors / metastases / pneumothorax
  •  go-up   go-down


75. Chen CH, Lai JM, Chou TY, Chen CY, Su LJ, Lee YC, Cheng TS, Hong YR, Chou CK, Whang-Peng J, Wu YC, Huang CY: VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway. PLoS One; 2009;4(4):e5052
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway.
  • BACKGROUND: Lung adenocarcinoma is the leading cause of cancer-related deaths among both men and women in the world.
  • Despite recent advances in diagnosis and treatment, the mortality rates with an overall 5-year survival of only 15%.
  • Although several well-known markers correlated with poor/metastasis prognosis in lung adenocarcinoma patients by immunohistochemistry was reported, the molecular mechanisms of lung adenocarcinoma development are still not clear.
  • To explore novel molecular markers and their signaling pathways will be crucial for aiding in treatment of lung adenocarcinoma patients.
  • METHODOLOGY/PRINCIPAL FINDINGS: To identify novel lung adenocarcinoma-associated /metastasis genes and to clarify the underlying molecular mechanisms of these targets in lung cancer progression, we created a bioinformatics scheme consisting of integrating three gene expression profile datasets, including pairwise lung adenocarcinoma, secondary metastatic tumors vs. benign tumors, and a series of invasive cell lines.
  • Among the novel targets identified, FLJ10540 was overexpressed in lung cancer tissues and is associated with cell migration and invasion.
  • Lung adenocarcinoma array profiles and tissue microarray IHC staining data showed that FLJ10540 and VEGF-A, as well as FLJ10540 and phospho-AKT exhibit positive correlations, respectively.
  • Stimulation of lung cancer cells with VEGF-A results in an increase in FLJ10540 protein expression and enhances complex formation with PI3K.
  • CONCLUSIONS/SIGNIFICANCE: This finding set the stage for further testing of FLJ10540 as a new therapeutic target for treating lung cancer and may contribute to the development of new therapeutic strategies that are able to block the PI3K/AKT pathway in lung cancer cells.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Cycle Proteins / physiology. Lung Neoplasms / pathology. Neoplasm Invasiveness. Neoplasm Metastasis. Nuclear Proteins / physiology. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Up-Regulation / physiology. Vascular Endothelial Growth Factor A / physiology
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. Enzyme Activation. Gene Knockdown Techniques. Humans. Microscopy, Fluorescence. RNA, Messenger / genetics. RNA, Small Interfering. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2002 Apr;1(3):219-27 [12086857.001]
  • [Cites] Nature. 1999 Dec 2;402(6761):483-7 [10591207.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):362-74 [12724734.001]
  • [Cites] J Pathol. 2003 Jul;200(3):336-47 [12845630.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):660-4 [12869408.001]
  • [Cites] Biochem Soc Trans. 2003 Dec;31(Pt 6):1171-7 [14641020.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):294-300 [14656735.001]
  • [Cites] Mol Ther. 2004 Apr;9(4):510-8 [15093181.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):423-36 [15170445.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):32592-602 [15145941.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6865-71 [15501963.001]
  • [Cites] Apoptosis. 2004 Nov;9(6):667-76 [15505410.001]
  • [Cites] Cancer Metastasis Rev. 1996 Dec;15(4):507-25 [9034607.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):64-8 [9036871.001]
  • [Cites] Am J Respir Cell Mol Biol. 1997 Sep;17(3):353-60 [9308922.001]
  • [Cites] Br J Cancer. 1997;76(8):1041-5 [9376264.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):589-93 [11212254.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3986-97 [11358816.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5223-30 [11431363.001]
  • [Cites] Langenbecks Arch Surg. 2001 Jul;386(4):293-301 [11466572.001]
  • [Cites] FASEB J. 2001 Sep;15(11):1953-62 [11532975.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 19;93(18):1392-400 [11562390.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3410-5 [11705856.001]
  • [Cites] Br J Cancer. 2002 Feb 12;86(4):558-63 [11870537.001]
  • [Cites] Science. 2002 May 31;296(5573):1655-7 [12040186.001]
  • [Cites] J Biol Chem. 1997 Dec 19;272(51):32521-7 [9405464.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1483-7 [9626466.001]
  • [Cites] J Biol Chem. 1999 Apr 9;274(15):10002-7 [10187776.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Oct;160(4):1269-73 [10508818.001]
  • [Cites] Lung. 2004;182(3):151-62 [15526754.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Nov 15;170(10):1088-94 [15317667.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Dev Cell. 2005 Oct;9(4):477-88 [16198290.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 16;338(2):830-8 [16256070.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7443-54 [16288291.001]
  • [Cites] Mol Cell. 2005 Nov 23;20(4):539-50 [16307918.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):46-51 [16397214.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):306-14 [16330671.001]
  • [Cites] Oncogene. 2006 Jan 19;25(3):480-6 [16170351.001]
  • [Cites] Genomics. 2006 Feb;87(2):243-53 [16406728.001]
  • [Cites] Oncogene. 2006 Jan 26;25(4):609-21 [16158046.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1354-62 [16452189.001]
  • [Cites] Cancer Lett. 2006 Apr 8;235(1):53-9 [15899546.001]
  • [Cites] Cell Cycle. 2006 Mar;5(6):603-5 [16582622.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):23285-95 [16787925.001]
  • [Cites] Mol Biol Cell. 2006 Sep;17(9):3881-96 [16790497.001]
  • [Cites] Curr Opin Investig Drugs. 2007 Feb;8(2):140-9 [17328230.001]
  • [Cites] J Biol Chem. 2007 Mar 16;282(11):7758-69 [17178724.001]
  • [Cites] Oncogene. 2007 Jun 21;26(29):4272-83 [17237822.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Aug;63(2):172-82 [17540577.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Behav Brain Res. 2002 Nov 15;136(2):489-501 [12429412.001]
  • (PMID = 19337377.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cep55 protein, human; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Vascular Endothelial Growth Factor A; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC2659802
  •  go-up   go-down


76. Veronesi G, Bellomi M, Mulshine JL, Pelosi G, Scanagatta P, Paganelli G, Maisonneuve P, Preda L, Leo F, Bertolotti R, Solli P, Spaggiari L: Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for baseline lung nodules. Lung Cancer; 2008 Sep;61(3):340-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for baseline lung nodules.
  • BACKGROUND: Indeterminate non-calcified lung nodules are frequent when low-dose spiral computed tomography (LD-CT) is used for lung cancer screening.
  • Protocol failures were delayed diagnosis with disease progression beyond stage I, and negative surgical biopsy.
  • Ninety-two lung cancers were diagnosed: 55 at baseline and 37 at annual screening (66% stage I).
  • In 15 of 104 (14%) invasive diagnostic procedures, the lesion was benign.
  • CONCLUSIONS: The protocol limits invasive diagnostic procedures while few patients have diagnosis delay, supporting the feasibility of lung cancer screening in high-risk subjects by LD-CT.
  • [MeSH-major] Lung Neoplasms / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Aged. Chi-Square Distribution. Contrast Media. Disease Progression. Female. Fluorodeoxyglucose F18. Humans. Incidence. Male. Mass Screening / methods. Middle Aged. Neoplasm Staging. Positron-Emission Tomography / methods. Prospective Studies. Radiation Dosage. Radiographic Image Interpretation, Computer-Assisted. Radiopharmaceuticals. Sensitivity and Specificity. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18308420.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


77. Zhang H, Zhao Q, Chen Y, Wang Y, Gao S, Mao Y, Li M, Peng A, He D, Xiao X: Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas. Thorax; 2008 Apr;63(4):352-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas.
  • This study was undertaken to investigate the possibility that overexpression of S100A7 protein might be detected in the sera of patients with lung cancer.
  • METHODS: RNA and protein levels of S100A7 were examined in 60 pairs of frozen lung cancer tissues by RT-PCR and western blot.
  • The specific expression of this protein and its cellular distribution were investigated in 145 paraffin embedded lung cancer samples, six benign lung disease and 21 normal lung tissues by immunohistochemistry.
  • The S100A7 protein level was further analysed in serum from 112 patients with lung cancer, 20 with benign lung diseases and 31 healthy individuals by ELISA.
  • RESULTS: Specific expression of both S100A7 mRNA and protein was found in squamous cell carcinomas, adenosquamous carcinomas and large cell lung carcinomas, whereas neither was detected in adenocarcinomas or paired non-cancerous lung tissues.
  • Further immunohistochemical analysis identified positive staining of S100A7 only in squamous cell carcinomas and large cell lung carcinomas, but not in other subtypes of lung cancer and normal lung tissues.
  • Weak expression was also found in the inflammatory cells of benign lung diseases.
  • CONCLUSION: S100A7 was only expressed in squamous cell carcinomas and large cell lung carcinomas and an increase in the level of S100A7 protein in serum may serve as a potential marker for lung cancer diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Calcium-Binding Proteins / metabolism. Carcinoma, Large Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Lung Neoplasms / diagnosis. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18364444.001).
  • [ISSN] 1468-3296
  • [Journal-full-title] Thorax
  • [ISO-abbreviation] Thorax
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Neoplasm Proteins; 0 / S100 Proteins; 0 / S100A7 protein, human
  •  go-up   go-down


78. Sun C, Wang XM, Liu C, Xv ZD, Wang DP, Sun XL, Deng K: Intravenous leiomyomatosis: diagnosis and follow-up with multislice computed tomography. Am J Surg; 2010 Sep;200(3):e41-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravenous leiomyomatosis: diagnosis and follow-up with multislice computed tomography.
  • Intravenous leiomyomatosis is a rare disease, which appears histologically benign but is clinically aggressive.
  • Multislice compute tomography (MSCT) allows an early and accurate preoperative diagnosis, resulting in a higher rate of surgical resection and improved survival.
  • [MeSH-major] Heart Neoplasms / radiography. Heart Neoplasms / surgery. Iliac Vein. Leiomyomatosis / radiography. Leiomyomatosis / surgery. Lung Neoplasms / radiography. Lung Neoplasms / surgery. Tomography, Spiral Computed. Vena Cava, Inferior
  • [MeSH-minor] Adult. Collateral Circulation. Diagnosis, Differential. Female. Humans. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Intravenous leiomyomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20409533.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Liu DH, Wang XM, Zhang LJ, Dai SW, Liu LY, Liu JF, Wu SS, Yang SY, Fu S, Xiao XY, He DC: Serum amyloid A protein: a potential biomarker correlated with clinical stage of lung cancer. Biomed Environ Sci; 2007 Feb;20(1):33-40
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum amyloid A protein: a potential biomarker correlated with clinical stage of lung cancer.
  • OBJECTIVE: To identify serum diagnosis or progression biomarkers in patients with lung cancer using protein chip profiling analysis.
  • METHOD: Profiling analysis was performed on 450 sera collected from 213 patients with lung cancer, 19 with pneumonia, 16 with pulmonary tuberculosis, 65 with laryngeal carcinoma, 55 with laryngopharyngeal carcinoma patients, and 82 normal individuals.
  • RESULTS: Profiling analysis demonstrated that an 11.6 kDa protein was significantly elevated in lung cancer patients, compared with the control groups (P < 0.001).
  • On the other hand, 11.6 kDa protein was also increased in 50% benign diseases of lung and 13% of other cancer controls.
  • CONCLUSION: SAA is a useful biomarker to monitor the progression of lung cancer and can directly identify some biomarkers on chip.
  • [MeSH-major] Biomarkers, Tumor / blood. Lung Neoplasms / blood. Serum Amyloid A Protein / analysis
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Small Cell / blood. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / pathology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Peptides / blood. Protein Array Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17458139.001).
  • [ISSN] 0895-3988
  • [Journal-full-title] Biomedical and environmental sciences : BES
  • [ISO-abbreviation] Biomed. Environ. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Peptides; 0 / Serum Amyloid A Protein
  •  go-up   go-down


80. Herder GJ, Kramer H, Hoekstra OS, Smit EF, Pruim J, van Tinteren H, Comans EF, Verboom P, Uyl-de Groot CA, Welling A, Paul MA, Boers M, Postmus PE, Teule GJ, Groen HJ, POORT Study Group: Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol; 2006 Apr 20;24(12):1800-6
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study.
  • METHODS: At first presentation, patients with a provisional diagnosis of lung cancer without overt dissemination were randomly assigned to traditional work-up (TWU) according to international guidelines or early PET followed by histologic/cytologic verification of lesions, or imaging and follow-up.
  • Patients with [18F] fluorodeoxyglucose (18FDG) -avid, noncentral tumors without suspicion of mediastinal or distant metastases on PET proceeded directly to thoracotomy.
  • Follow-up in presumed benign lesions was at least 12 months.
  • CONCLUSION: Up-front 18FDG-PET in patients with (suspected) lung cancer does not reduce the overall number of diagnostic test, but it maintains quality of TNM staging with the use of less invasive surgery.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Lung Neoplasms / radionuclide imaging. Neoplasm Staging / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Apr 20;24(12):1785-7 [16567767.001]
  • (PMID = 16567772.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


81. Eloubeidi MA, Cerfolio RJ, Chen VK, Desmond R, Syed S, Ojha B: Endoscopic ultrasound-guided fine needle aspiration of mediastinal lymph node in patients with suspected lung cancer after positron emission tomography and computed tomography scans. Ann Thorac Surg; 2005 Jan;79(1):263-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic ultrasound-guided fine needle aspiration of mediastinal lymph node in patients with suspected lung cancer after positron emission tomography and computed tomography scans.
  • BACKGROUND: The treatment of patients with non-small cell lung cancer (NSCLC) depends on the stage.
  • The reference standard included thoracotomy with complete lymphadenectomy in patients with lung cancer or if EUS-FNA was benign, repeat clinical imaging, or long-term follow-up.
  • [MeSH-major] Biopsy, Fine-Needle. Carcinoma, Non-Small-Cell Lung / secondary. Esophagoscopy. Lung Neoplasms / pathology. Lymphatic Diseases / pathology. Lymphatic Metastasis / pathology. Neoplasm Staging / methods. Positron-Emission Tomography. Tomography, X-Ray Computed. Ultrasonography, Interventional
  • [MeSH-minor] Aged. Breast Neoplasms / pathology. Carcinoma / pathology. Carcinoma / radiography. Carcinoma / radionuclide imaging. Carcinoma / secondary. Carcinoma / ultrasonography. Colonic Neoplasms / pathology. Endometrial Neoplasms / pathology. Female. Fluorodeoxyglucose F18. Granuloma / diagnosis. Histiocytosis / complications. Histiocytosis / diagnosis. Histoplasmosis / complications. Histoplasmosis / diagnosis. Humans. Kidney Neoplasms / pathology. Lung Diseases / complications. Lymphoma / pathology. Lymphoma / radiography. Lymphoma / radionuclide imaging. Lymphoma / ultrasonography. Male. Mediastinum. Middle Aged. Predictive Value of Tests. Prospective Studies. Radiopharmaceuticals. Sarcoidosis / complications. Sarcoidosis / diagnosis. Silicosis / complications. Silicosis / diagnosis. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15620955.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


82. Silva CT, Amaral JG, Moineddin R, Doda W, Babyn PS: CT characteristics of lung nodules present at diagnosis of extrapulmonary malignancy in children. AJR Am J Roentgenol; 2010 Mar;194(3):772-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT characteristics of lung nodules present at diagnosis of extrapulmonary malignancy in children.
  • OBJECTIVE: The purpose of this study was to evaluate the CT characteristics of lung nodules present at diagnosis of extrapulmonary malignancies in children.
  • Images were reviewed for the presence of lung nodules; if present, the following nodular characteristics were recorded: sidedness, number, distribution, CT attenuation, shape, margins, calcification, and size.
  • RESULTS: One hundred eleven infants and children (age range, 14 days-17 years 10 months; median age, 11 years 8 months) had lung nodules on CT.
  • The nodules showed a variety of patterns, but the most common findings were bilateral lung nodules (71 of 111 patients), between two and 10 in number (60 patients), peripheral distribution (98 patients), < or = 5 mm (48 patients), oval shape (45 patients), solid attenuation (74 patients), smoothly marginated (91 patients), and noncalcified (107 patients).
  • Seventeen biopsies showed benign lesions and nine, malignant lesions; the results for the remaining biopsy were inconclusive.
  • In the subgroup of lung nodules that underwent biopsy, none of the CT characteristics was able to differentiate benignity from malignancy.
  • CONCLUSION: Lung nodules in children with extrapulmonary malignancies showed a variety of patterns on CT.
  • In the subgroup of lung nodules that underwent biopsy, none of the nodule features studied on CT reliably differentiated benignity from malignancy.
  • [MeSH-major] Lung Neoplasms / pathology. Lung Neoplasms / radiography. Neoplasms, Multiple Primary / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Logistic Models. Male. Neoplasm Staging. Retrospective Studies

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] AJR Am J Roentgenol. 2010 Oct;195(4):W308; author reply W309-W310 [20858796.001]
  • (PMID = 20173158.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Annema JT, Versteegh MI, Veseliç M, Voigt P, Rabe KF: Endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of lung cancer and its impact on surgical staging. J Clin Oncol; 2005 Nov 20;23(33):8357-61
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of lung cancer and its impact on surgical staging.
  • PURPOSE: The diagnosis and staging of lung cancer critically depends on surgical procedures.
  • Endoscopic ultrasound (EUS) -guided fine-needle aspiration (FNA) is an accurate, safe, and minimally invasive technique for the analysis of mediastinal lymph nodes (LNs) and can additionally detect tumor invasion (T4) in patients with centrally located tumors.
  • PATIENTS AND METHODS: Two hundred forty two consecutive patients with suspected (n = 142) or proven (n = 100) lung cancer and enlarged (> 1 cm) mediastinal LNs at chest computed tomography were scheduled for mediastinoscopy/tomy (94%) or exploratory thoracotomy (6%).
  • If EUS-FNA established LN metastases, tumor invasion, or small-cell lung cancer (SCLC), scheduled surgical interventions were cancelled.
  • RESULTS: EUS-FNA prevented 70% of scheduled surgical procedures because of the demonstration of LN metastases in non-small-cell lung cancer (52%), tumor invasion (T4) (4%), tumor invasion and LN metastases (5%), SCLC (8%), or benign diagnoses (1%).
  • CONCLUSION: EUS-FNA qualifies as the initial staging procedure of choice for patients with (suspected) lung cancer and enlarged mediastinal LNs.
  • Implementation of EUS-FNA in staging algorithms for lung cancer might reduce the number of surgical staging procedures considerably.
  • [MeSH-major] Biopsy, Fine-Needle / instrumentation. Endosonography. Lung Neoplasms / pathology. Lung Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Female. Humans. Lymphatic Metastasis. Male. Mediastinum. Middle Aged. Neoplasm Staging / instrumentation. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Oncol. 2005 Nov 20;23(33):8283-5 [16219928.001]
  • (PMID = 16219935.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comment; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


84. Langfort R, Rudziński P, Burakowska B: [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment]. Pneumonol Alergol Pol; 2010;78(1):33-46
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment].
  • Neuroendocrine tumors of the lung represent a broad spectrum of morphologic types that share specific morphologic, immunohistochemical, ultrastructural, and molecular characteristics.
  • The classification of neuroendocrine lung tumors has changed over the last decades and currently four categories are distinguished: typical carcinoid tumor, atypical carcinoid tumor, large cell neuroendocrine carcinoma and small cell carcinoma.
  • Neuroendocrine tumors of the lung comprise approximately 20% of all primary lung cancers.
  • Because of differences in clinical behavior, therapy, and prognosis, a reliable histological diagnosis, as well as clinical and pathological staging system are essential for an appropriate medical proceedings.
  • All carcinoids are malignant tumors with the potential to metastasize.
  • Large cell neuroendocrine and small cell carcinoma progress rapidly and are generally widespread at the moment of diagnosis.
  • Increased knowledge about pulmonary neuroendocrine tumors biology and the genetic characteristics, imply that carcinoid tumors appear to have a different etiology and pathogenesis than large cell neuroendocrine and small cell carcinoma.
  • In practice, it could be easiest to conceptualize this group of pulmonary tumors as a spectrum of malignancy ranging from the low grade typical carcinoid to the highly malignant large cell neuroendocrine and small cell carcinoma.
  • Typical carcinoid tumors associated with a fairly benign behavior should be classified as low-grade neuroendocrine tumor/carcinoma (G1) and atypical carcinoid tumors as intermediate-grade tumor/carcinoma (G2).
  • Whereas, large cell neuroendocrine and small cell carcinoma should be grouped together under the designation of high-grade neuroendocrine tumor/carcinoma (G3).
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / therapy. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / therapy
  • [MeSH-minor] Carcinoid Tumor / diagnosis. Carcinoid Tumor / therapy. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / therapy. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / therapy. Humans. Lung / pathology. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20162517.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 67
  •  go-up   go-down


85. Gao J, Wang H, Qi J: [Detection of serum CK19-2G2 and Cyfra21-1 protein and comparison of their diagnostic value for lung cancer]. Zhonghua Zhong Liu Za Zhi; 2008 Dec;30(12):930-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of serum CK19-2G2 and Cyfra21-1 protein and comparison of their diagnostic value for lung cancer].
  • OBJECTIVE: To evaluate and compare the value of serum CK19-2G2 and Cyfra21-1 in diagnosis of lung cancer.
  • METHODS: The serum concentration of CK19-2G2 and Cyfra21-1 was detected in 104 patients with lung cancer, 71 with benign lung diseases and 105 healthy volunteers.
  • The value of the two parameters in the diagnosis of lung cancer was evaluated with ROC curve analysis.
  • RESULTS: The mean serum CK19-2G2 concentration in the lung cancer group was 2.87 mU/ml, significantly higher than that in the group with benign lung diseases (1.02 mU/ml) and healthy volunteer group (0.01 mU/ml) (P = 0.000).
  • CONCLUSION: CK19-2G2, with a higher specificity, may be a better tumor marker than CK19-2G2 in respect of specificity for non-small cell lung cancer (NSCLC), especially for squamous lung carcinoma, and deserves further study.
  • [MeSH-major] Antigens, Neoplasm / blood. Carcinoma, Squamous Cell / diagnosis. Keratin-19 / blood. Lung Neoplasms / diagnosis. Peptide Fragments / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Female. Humans. Male. Middle Aged. Small Cell Lung Carcinoma / blood. Small Cell Lung Carcinoma / diagnosis. Young Adult

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173996.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-19; 0 / Peptide Fragments; 0 / antigen CYFRA21.1
  •  go-up   go-down


86. De Wever W, Stroobants S, Coolen J, Verschakelen JA: Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. Eur Respir J; 2009 Jan;33(1):201-12
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration.
  • Lung cancer is a common disease and is a leading cause of death in many countries.
  • The management of lung cancer is directed by an optimal staging of the tumour.
  • This improvement can result in the detection of lesions initially not seen on CT or PET, a more precise location of lesions, a better characterisation of the lesion as benign or malignant and a better differentiation between tumour and surrounding structures.
  • Initial studies demonstrate better results for PET/CT in the staging of lung cancer in comparison with PET alone, CT alone or visual correlation of PET and CT.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Lung Neoplasms / diagnosis. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Humans. Neoplasm Staging. Reproducibility of Results

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19118231.001).
  • [ISSN] 1399-3003
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 65
  •  go-up   go-down


87. Choi KH, Baek HA, Park HS, Jang KY, Jin GY, Kim MH, Lee YC, Moon WS, Chung MJ: Sclerosing hemangioma, presenting as a pneumonic pattern with mucinous adenomatous hyperplasia of the lung. Pathol Int; 2008 Nov;58(11):735-40
Genetic Alliance. consumer health - Hemangioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing hemangioma, presenting as a pneumonic pattern with mucinous adenomatous hyperplasia of the lung.
  • Pulmonary sclerosing hemangioma is generally considered a rare neoplasm presenting as a solitary benign nodule.
  • During routine medical examination multiple abnormal nodular shadows were detected in the right lower lung field on chest X-ray in a 48-year-old asymptomatic woman.
  • The resected lung had numerous scattered tiny nodules and small nodules congregated together, forming larger nodules.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Hyperplasia. Immunoenzyme Techniques. Middle Aged. Nuclear Proteins / analysis. Pneumonia / pathology. Radiography, Thoracic. Transcription Factors / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18844941.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


88. Chen YQ, Li DM, Cai YY, Liu C, Xia XM, Hu JF: [The expression of survivin messenger RNA in sputum and cancerous tissue in human lung cancer]. Zhonghua Jie He He Hu Xi Za Zhi; 2005 Apr;28(4):225-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expression of survivin messenger RNA in sputum and cancerous tissue in human lung cancer].
  • OBJECTIVE: To study the diagnostic significance of the expression of survivin mRNA in transbronchial biopy samples and sputum samples in lung cancer.
  • METHODS: The resected lung cancer tissues and their para-carcinomatous normal tissue specimens of 41 patients with lung cancer and tissue specimens of 9 patients with benign pulmonary diseases were studied.
  • 110 bronchial biopsy specimens from 80 patients with lung cancer and 30 patients with benign pulmonary diseases and their 160 sputum samples were also evaluated.
  • (1) The positive rate of survivin mRNA in resected lung cancer tissues (29/41; 70.7%) was higher than that in the para-carcinomatous normal tissues (7/41; 17.1%) and the benign pulmonary tissues (1/9; 11.1%, P < 0.05).
  • There was no statistical difference (P > 0.05) in the positive rate of survivin mRNA between para-carcinomatous normal tissues and the benign pulmonary disease tissues.
  • In the bronchial biopsy samples, the positive rate of survivin mRNA in 80 lung cancer tissues (51/80; 63.8%) was also higher than that in the benign pulmonary tissues (4/30; 13.3%, P < 0.05).
  • The sensitivity and specificity of diagnosis for lung cancer by detecting survivin mRNA in resected cancer tissue and transbronchial biopsy tissue were 63.8% - 70.7% and 86.7% - 88.9%, respectively. (2) The sensitivity of cytological examinations combined with detecting survivin mRNA in sputum samples was higher than that of either cytological examination or survivin mRNA detection of sputum samples alone (P < 0.05).
  • The sensitivity of the diagnosis for lung cancer increased from 47.1% (sputum cytology alone) to 80.2% (sputum survivin mRNA detection combined with sputum cytology, P < 0.05) and the negative predictive value increased from 37.9% for sputum cytology alone to 57.9% (P < 0.01) for sputum survivin mRNA detection combined with sputum cytology.
  • CONCLUSIONS: Detecting survivin mRNA expression from bronchial biopsy specimens might be used as one of the specific molecular markers for diagnosis of lung cancer, while the detection of survivin mRNA from sputum samples as a new ancillary diagnostic method for lung cancer.
  • [MeSH-major] Biopsy / methods. Lung Neoplasms / diagnosis. Microtubule-Associated Proteins / genetics. Sputum / chemistry
  • [MeSH-minor] Adult. Aged. Bronchoscopy. Female. Humans. Inhibitor of Apoptosis Proteins. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Biopsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854429.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins
  •  go-up   go-down


89. Zhao Z, Huang Q, Zhao T, Zhao J: [Expression and clinical significance of PML, P53 and P16INK4A in lung cancer]. Zhongguo Fei Ai Za Zhi; 2007 Jun 20;10(3):176-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of PML, P53 and P16INK4A in lung cancer].
  • BACKGROUND: The promyelocytic leukaemia (PML) protein has been implicated in control of key tumor-suppressive pathways.
  • However, its role in pathogenesis of lung cancer is still unclear.
  • The objective of this study is to assess expression and clinical significance of PML, P53 and P16INK4A in lung cancer, as well as the relation of these factors.
  • METHODS: The tissue microarrays were created with samples from lung cancers (n=148), pulmonary benign lung tumors (n=5) and normal lung tissues (n=7), and protein expression was analyzed by immunohistochemical staining.
  • RESULTS: There was at least triplicate 0.6-mm cores per sample, 4 cases of lung cancer were excluded for lacking of enough tissue.
  • P53 expression was found in 33.3% lung cancer, and absent in benign tumors and normal tissues of the lung (P=0.038).
  • P16INK4A expression was abolished in normal lung tissue, however, increased in lung cancer (28.5%), and especially in lung cancer with non- or poor differentiation (36.5%) and in SCLC (69.6%).
  • There was inverse correlation between PML expression in the nuclei and P16INK4A expression, positive correlation between P53 and P16INK4A expressions in lung cancers.
  • CONCLUSIONS: As an important suppressor of tumor, PML is related with P53 mutation in squamous cell carcinoma.
  • Increased P16INK4A protein in lung cancer may be the results of gene mutation, and be related with mutant P53 protein.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21118641.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


90. Vaideeswar P: Sclerosing hemangioma with lymph nodal metastases. Indian J Pathol Microbiol; 2009 Jul-Sep;52(3):392-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case of sclerosing hemangioma of the lung is reported in a young male, who presented with recurrent cough and streaky hemoptysis for three years.
  • The tumor was situated in the right upper lobe and was large (over 9 cm), multicentric and associated with metastases to the regional lymph nodes.
  • [MeSH-major] Histiocytoma, Benign Fibrous / diagnosis. Histiocytoma, Benign Fibrous / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Lymphatic Metastasis / pathology. Neoplasm Metastasis / pathology

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19679971.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


91. Cordeiro SZ, Cordeiro Pde B, Sousa AM, Lannes DC, Pierro GS: Giant cell tumor of the rib occupying the entire hemithorax. J Bras Pneumol; 2008 Mar;34(3):185-8
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the rib occupying the entire hemithorax.
  • The authors report the case of a 28-year-old female patient with a giant cell tumor originating from the rib.
  • The tumor, measuring 25 x 17 cm, occupied the entire hemithorax and caused atelectasis of the left lung.
  • This tumor was a benign mesenchymal neoplasm, which rarely affects the ribs.
  • A thoracotomy involving en bloc resection of the chest wall and tumor was performed.
  • Despite the large dimensions of the tumor, complete resection was possible, and lung function was restored.
  • [MeSH-major] Bone Neoplasms / diagnosis. Giant Cell Tumor of Bone / diagnosis. Ribs

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392468.001).
  • [ISSN] 1806-3756
  • [Journal-full-title] Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  • [ISO-abbreviation] J Bras Pneumol
  • [Language] eng; por
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


92. Koga T, Ushijima K, Kage M, Ichiki M, Kitajima T, Narita Y, Mizoguchi Y, Hanada M, Ehara R, Nishimura M, Takamori S, Aizawa H: Pulmonary metastasis of endometrial stromal sarcoma. Kurume Med J; 2006;53(3-4):95-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple round opacities suggestive of metastatic lung tumors were incidentally found on a chest x-ray film in a 43-year-old woman.
  • Morphological characteristics of the thracoscopically resected lung tumors suggested low-grade endometrial stromal sarcoma (ESS), and immunostaining revealed that the tumor cells were positive for progesterone and estrogen receptors, CD10 and vimentin, confirming a diagnosis of ESS.
  • ESS is an uncommon uterine neoplasm, however, may be mistaken as benign tumors such as epithelioid leiomyoma, and occasionally metastasizes to remote organs such as lungs even after long disease-free period, posing diagnostic challenge.
  • [MeSH-major] Endometrial Neoplasms / pathology. Lung Neoplasms / secondary. Sarcoma, Endometrial Stromal / pathology

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317938.001).
  • [ISSN] 0023-5679
  • [Journal-full-title] The Kurume medical journal
  • [ISO-abbreviation] Kurume Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


93. Spanu A, Schillaci O, Pirina P, Arru A, Madeddu G, Chessa F, Marongiu P, Solinas ME, Madeddu G: 99mTc-tetrofosmin SPECT in solitary pulmonary nodule evaluation. Oncol Rep; 2006 Oct;16(4):763-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A correct differential diagnosis between benign and malignant lesions is mandatory in patients with solitary pulmonary nodule (SPN).
  • A consecutive series of 111 patients with an uncalcified </=3 cm (range: 0.8-3 cm) SPN, without definite benign findings and indeterminate at CT, were studied.
  • The images were analysed both qualitatively and semiquantitatively by calculating tumor/normal tissue ratio (T/N).
  • All nodules were referred to a definitive diagnosis after scintigraphy: 84/111 nodules resulted malignant (primary lung carcinomas in 59 cases and metastases in 25), whereas 27/111 were benign.
  • SPECT was true negative in 24/27 benign lesions (specificity: 88.9%) and false positive in 2 hamartomas and in 1 aspecific inflammation (range size: 0.8-2 cm), each with a T/N value </=1.4.
  • Mean T/N value was significantly higher in malignant than in benign nodules (2.1+/-0.6 vs. 1.3+/-0.1, P<0.05), whereas no significant differences were observed between primary lung carcinomas and metastases (2.1+/-0.6 vs. 1.9+/-0.6) or in the different histologic types of carcinomas.
  • 99mTc-tetrofosmin SPECT proved a highly sensitive imaging method in both primary and secondary malignant </=3 cm SPNs detection, with a high accuracy value in discriminating malignant from benign lesions, also by adding semiquantitative analysis.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / radiography. Organophosphorus Compounds. Organotechnetium Compounds. Radiopharmaceuticals. Solitary Pulmonary Nodule / diagnosis. Tomography, Emission-Computed, Single-Photon / methods
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Radiographic Image Interpretation, Computer-Assisted. Radionuclide Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16969491.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


94. Uygun K, Kocak Z, Altaner S, Cicin I, Tokatli F, Uzal C: Colonic metastasis from carcinoma of the breast that mimics a primary intestinal cancer. Yonsei Med J; 2006 Aug 31;47(4):578-82
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the lung, liver, or bones are the most common location for distant metastases in breast cancer patients, metastases to the intestinal tract are very rarely recognized in the clinic.
  • Despite the fact that isolated gastrointestinal (GI) metastases are very rare and much less common than benign disease processes or second primaries of the intestinal tract in patients with a history of breast cancer, metastatic disease should be given consideration whenever a patient experiences GI symptoms.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Colonic Neoplasms / diagnosis. Colonic Neoplasms / secondary. Intestinal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Breast / pathology. Diagnosis, Differential. Female. Humans. Neoplasm Metastasis. Neoplasms, Second Primary / diagnosis. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1998 Jan;93(1):111-4 [9448188.001]
  • [Cites] Histopathology. 1996 Sep;29(3):233-40 [8884351.001]
  • [Cites] Am J Gastroenterol. 2000 Oct;95(10):3014-6 [11051411.001]
  • [Cites] Eur J Surg Oncol. 2002 Jun;28(4):463-4 [12099661.001]
  • [Cites] Am J Dig Dis. 1972 Oct;17(10):881-6 [5073677.001]
  • [Cites] J Surg Oncol. 1979;11(3):193-205 [459515.001]
  • [Cites] Dis Colon Rectum. 1988 May;31(5):401-2 [3366041.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):181-7 [2910416.001]
  • [Cites] Int J Biol Markers. 1988 Jan-Mar;3(1):41-8 [2854832.001]
  • [Cites] Hum Pathol. 1991 Apr;22(4):368-72 [2050370.001]
  • [Cites] Gastrointest Endosc. 1992 Mar-Apr;38(2):136-41 [1568609.001]
  • [Cites] Am J Clin Oncol. 1992 Aug;15(4):365-9 [1514536.001]
  • [Cites] J Surg Oncol. 1992 Nov;51(3):211-5 [1434649.001]
  • [Cites] Med Klin (Munich). 1992 Dec 15;87(12):631-6 [1287424.001]
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):681-2 [10919011.001]
  • (PMID = 16941751.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2687742
  •  go-up   go-down


95. Vilmann P, Krasnik M, Larsen SS, Jacobsen GK, Clementsen P: Transesophageal endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) biopsy: a combined approach in the evaluation of mediastinal lesions. Endoscopy; 2005 Sep;37(9):833-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND STUDY AIMS: It would be desirable to develop minimally invasive methods of tissue diagnosis from lymph nodes as well as solid lesions in the mediastinum.
  • PATIENTS AND METHODS: EUS-FNA and EBUS-TBNA were compared in 33 patients, for the staging of lung cancer in patients with an established diagnosis of non-small-cell lung cancer (n = 20) or for diagnosis of a suspicious mediastinal lesion in patients with suspected lung cancer (n = 13).
  • EUS-FNA and EBUS-TBNA demonstrated cancer in 26 and 28 lesions, respectively, and benign cytology in 30 and 28 lesions, respectively.
  • Conversely, EUS-FNA diagnosed 12 additional cancer diagnoses, one suspicious and one specific benign diagnosis (sarcoidosis) in addition to EBUS-TBNA.
  • With a combined approach (EUS-FNA + EBUS-TBNA) in 28 of the 31 patients in whom a final diagnosis was obtained in the evaluation of mediastinal cancer, 20 patients were found to have mediastinal involvement, whereas no mediastinal metastases were found in eight patients.
  • The accuracy of EUS-FNA and EBUS-TBNA, in combination, for the diagnosis of mediastinal cancer was 100 % (95 % CI, 83 - 100 %).
  • A combined approach with both EUS-FNA and EBUS-TBNA may be able to replace more invasive methods for evaluating lung cancer patients with suspected hilar or mediastinal metastases, as well as for evaluating unclear mediastinal or hilar lesions.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Carcinoma, Non-Small-Cell Lung / pathology. Endosonography. Lung Neoplasms / pathology. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Bronchi. Esophagus. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16116534.001).
  • [ISSN] 0013-726X
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


96. Smati B, Boudaya MS, Mestiri T, Djilani H, Mezni F, Kilani T: [Endobronchial hamartoma revealed by hemoptysis]. Tunis Med; 2005 May;83(5):292-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hamartoma is the most frequent benign tumor of the lung.
  • A histological examination confirmed the diagnosis of endo bronchial hamartoma.
  • CONCLUSION: Diagnosis of endobronchial hamartoma before surgery is difficult.
  • [MeSH-major] Hamartoma / pathology. Hamartoma / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Pneumonectomy
  • [MeSH-minor] Adult. Airway Obstruction / etiology. Diagnosis, Differential. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044904.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


97. Afify AM, Stern R, Michael CW: Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Diagn Cytopathol; 2005 Mar;32(3):145-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Archival paraffin-embedded cell blocks of serous fluids from 28 cases of reactive mesothelial cells, 14 cases of MM, 20 cases of metastatic ovarian carcinomas, 17 cases of metastatic breast carcinomas, 12 cases of metastatic lung ACA, and 12 cases of metastatic gastrointestinal ACA were stained with HA using a biotinylated HABP and CD44S.
  • All MMs and 93% (26/28) of the benign mesothelial cells were positive for intracytoplasmic HA vs. none of ACAs.
  • CD44S was expressed in 100% (28/28) of mesothelial hyperplesia, 86% (12/14) of MMs, 70% (14/20) of ovarian carcinomas, 29% (5/17) of breast carcinomas, 25% (3/12) of gastrointestinal ACAs, and 8% (1/12) of lung ACAs.
  • CD44 may prove useful in conjunction with other stains in the differential diagnosis of mesothelioma and ADA.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, CD44 / metabolism. Ascitic Fluid / metabolism. Hyaluronic Acid / metabolism. Mesothelioma / diagnosis. Pleural Effusion, Malignant / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Neoplasm Metastasis. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15690337.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44S antigen; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


98. Lu CR, Hu YJ, Chen EG, Qiu YH, Ying KJ: [Measurement of exhaled volatile organic compounds in lung cancer patients]. Zhonghua Jie He He Hu Xi Za Zhi; 2010 Feb;33(2):104-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Measurement of exhaled volatile organic compounds in lung cancer patients].
  • OBJECTIVE: to study the characteristics of volatile organic compounds (VOCs) in exhaled breath of lung cancer patients, and therefore to explore its use in the diagnosis of the disease.
  • METHODS: from February 2007 to September 2009, 55 patients with lung cancer, 21 patients with benign lung diseases and 30 healthy controls were enrolled in our study.
  • RESULTS: heptanal was detected in 45 patients of the lung cancer group, 1 of the benign lung disease group, and 1 of the healthy control group.
  • The positive rate was higher in the lung cancer group as compared to the benign lung disease group and the healthy group combined (P < 0.05).
  • CONCLUSION: heptanal maybe a useful marker in VOCs from patients with lung cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lung Neoplasms / diagnosis. Volatile Organic Compounds / analysis
  • [MeSH-minor] Breath Tests. Case-Control Studies. Exhalation. Female. Humans. Male. Middle Aged. Neoplasm Staging. Smoking

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20367949.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Volatile Organic Compounds; Adenocarcinoma of lung
  •  go-up   go-down


99. Oremek GM, Sauer-Eppel H, Bruzdziak TH: Value of tumour and inflammatory markers in lung cancer. Anticancer Res; 2007 Jul-Aug;27(4A):1911-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of tumour and inflammatory markers in lung cancer.
  • The aim of this study was to evaluate the individual diagnostic utility of tumour and inflammatory markers in patients with different pulmonary diseases.
  • The usefulness of neuron-specific enolase (NSE), carcino-embryonic antigen (CEA), serum pro-gastrin releasing peptide (ProGRP) and CYFRA 21-1, as tumour markers, and C-reactive protein (CRP) and tumour necrosis factor-alpha (TNFalpha) as inflammatory markers for diagnosis, treatment and monitoring of patients with different pulmonary afflictions was investigated.
  • Serum samples were also obtained from 20 patients suffering from bronchitis, 20 with lung fibrosis and 30 with sarcoidosis.
  • Moreover, serum marker levels were analyzed in 139 patients with different pulmonary malignancies: 29 patients with adenocarcinoma, 30 patients with squamous cell carcinoma, 80 patients with small cell lung cancer (SCLC).
  • All tumour markers showed significantly elevated values in malignant diseases.
  • The levels of ProGRP in patients with benign diseases were significantly higher than those in the healthy group (35.4 +/- 6.6 compared with 21.3 +/- 9.2 pg/ml respectively).
  • The elevation was significantly higher than that of the benign reference group.
  • Serum CRP levels were significantly higher in patients with SCLC (38.5 +/- 7.6 mg/dl) than in the benign reference group.
  • In conclusion, when serum tumour markers are abnormally elevated in patients with lung cancer, CEA, CYFRA 21-1, NSE and ProGRP are useful clinical markers, good indicators of disease extent and may have important prognostic value.
  • [MeSH-major] Biomarkers, Tumor / blood. Inflammation / blood. Lung Neoplasms / diagnosis
  • [MeSH-minor] Antigens, Neoplasm / blood. Area Under Curve. C-Reactive Protein / analysis. Carcinoembryonic Antigen / blood. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Small Cell / blood. Carcinoma, Small Cell / diagnosis. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / diagnosis. Humans. Immunoassay. Keratin-19. Keratins / blood. Lung Diseases / blood. Lung Diseases / diagnosis. Peptide Fragments / blood. Peptides / blood. Phosphopyruvate Hydratase / blood. ROC Curve. Recombinant Proteins / blood. Sensitivity and Specificity. Tumor Necrosis Factor-alpha / blood

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649794.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / Peptide Fragments; 0 / Peptides; 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; 0 / antigen CYFRA21.1; 0 / pro-gastrin-releasing peptide (31-98); 68238-35-7 / Keratins; 9007-41-4 / C-Reactive Protein; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


100. Vansteenkiste JF, Stroobants SS: PET scan in lung cancer: current recommendations and innovation. J Thorac Oncol; 2006 Jan;1(1):71-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET scan in lung cancer: current recommendations and innovation.
  • In the past 10 years, positron emission tomography (PET), usually with F-fluoro-2-deoxy-D-glucose (FDG), has become an important imaging modality in patients with lung cancer.
  • FDG-PET is recommended for the diagnosis of indeterminate pulmonary nodules, for which it is significantly more accurate than computed tomography (CT) in the distinction between benign and malignant lesions.
  • Ongoing studies now concentrate on more advanced clinical applications, such as the planning of radiotherapy, the response evaluation after the induction of therapy, the early detection of recurrence, and the use in lung cancer screening.
  • [MeSH-major] Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Practice Guidelines as Topic
  • [MeSH-minor] Diagnosis, Differential. Fluorodeoxyglucose F18. Humans. Neoplasm Staging / methods. Radiopharmaceuticals. Reproducibility of Results

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409830.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 19
  •  go-up   go-down






Advertisement